As	O
demonstrated	O
by	O
in	O
vitro	O
studies	O
,	O
cisplatin	B-I
(	I-I
CDDP	I-I
)	I-I
is	O
able	O
to	O
down-regulate	O
the	O
AGAT	O
activity	O
,	O
suggesting	O
that	O
CDDP	B-I
could	O
enhance	O
the	O
antitumor	B-OUT
activity	I-OUT
of	I-OUT
TMZ	I-OUT
.	I-OUT


Patient	B-P
and	I-P
tumor	I-P
characteristics	I-P
were	O
well	O
balanced	O
between	O
the	O
two	O
arms	O
.	O


Patients	B-P
with	I-P
cerebral	I-P
metastases	I-P
were	I-P
included	I-P
.	I-P


There	O
was	O
significantly	O
more	O
grade	B-OUT
3	I-OUT
and	I-OUT
4	I-OUT
emesis	I-OUT
in	O
the	O
combination	O
arm	O
.	O


CONCLUSIONS	O
No	B-OUT
clear	I-OUT
benefit	I-OUT
in	O
terms	O
of	O
response	B-OUT
rates	I-OUT
,	I-OUT
median	I-OUT
TTP	I-OUT
or	O
OS	O
was	O
shown	O
with	O
the	O
combination	O
of	O
TMZ	B-I
+	I-I
CDDP	I-I
.	I-I


Additionally	O
,	O
the	O
combination	O
was	O
associated	O
with	O
higher	O
incidence	O
of	O
grade	B-OUT
3	I-OUT
and	I-OUT
4	I-OUT
emesis	I-OUT
.	I-OUT


The	O
control	O
toothpaste	O
was	O
a	O
conventional	B-I
,	I-I
moderately	I-I
abrasive	I-I
paste	I-I
containing	I-I
0.8	I-I
%	I-I
sodium	I-I
monofluorophosphate	I-I
.	I-I


The	O
children	B-P
were	O
examined	O
clinically	O
and	O
radiologically	O
each	O
year	O
.	O


Caries	B-OUT
increments	I-OUT
after	O
3	O
years	O
,	O
in	O
terms	O
of	O
DMF	O
teeth	O
and	O
DMF	O
surfaces	O
,	O
showed	O
no	O
significant	O
differences	O
between	O
the	B-P
MFP	I-I
test	I-I
group	I-P
(	I-P
444	I-P
children	I-P
)	I-P
and	I-P
the	I-P
MFP	I-I
control	I-I
group	I-P
(	I-P
450	I-P
children	I-P
)	I-P
.	O


However	O
,	O
the	O
TMP	B-I
test	I-P
group	I-P
(	I-P
425	I-P
children	I-P
)	I-P
had	O
significantly	O
higher	O
caries	B-OUT
increments	I-OUT
than	O
the	O
MFP	B-I
control	I-I
group	O
.	O


Therapeutic	O
recommendations	B-OUT
in	O
polycythemia	O
vera	O
based	O
on	O
Polycythemia	O
Vera	O
Study	O
Group	O
protocols	O
.	O


With	O
respect	O
to	O
the	O
final	O
question	O
,	O
the	O
optimal	O
treatment	O
for	O
polycythemia	O
vera	O
,	O
it	O
is	O
apparent	O
that	O
the	O
expectation	O
of	O
a	O
single	B-I
optimal	I-I
therapy	I-I
that	O
would	O
apply	O
to	O
all	O
patients	O
at	O
all	O
ages	O
and	O
stages	O
of	O
the	O
disease	O
was	O
naive	O
.	O


Moreover	O
,	O
the	O
group	O
has	O
defined	O
more	O
precisely	O
than	O
ever	O
before	O
the	O
nature	B-OUT
of	I-OUT
the	I-OUT
complications	I-OUT
of	O
the	O
disease	O
and	O
the	O
association	O
of	O
the	O
risks	B-OUT
of	I-OUT
specific	I-OUT
complications	I-OUT
with	O
specific	O
forms	O
of	O
therapy	O
.	O


Environmental	B-I
enrichment	I-I
as	O
a	O
therapy	O
for	O
autism	B-P
:	I-P
A	O
clinical	O
trial	O
replication	O
and	O
extension	O
.	O


In	O
an	O
initial	O
randomized	O
controlled	O
trial	O
,	O
children	B-P
with	I-P
autism	I-P
who	I-P
received	I-P
sensorimotor	I-I
enrichment	I-I
at	I-I
home	I-I
for	I-P
6	I-P
months	I-P
had	I-P
significant	I-P
improvements	I-P
in	I-P
both	I-P
their	I-P
cognitive	I-P
ability	I-P
and	I-P
the	I-P
severity	I-P
of	I-P
their	I-P
autism	I-P
symptoms	I-P
(	O
Woo	O
&	O
Leon	O
,	O
2013	O
)	O
.	O


We	O
now	O
report	O
the	O
outcomes	O
of	O
a	O
similar	O
randomized	O
controlled	O
trial	O
in	O
which	O
children	B-P
with	I-P
autism	I-P
,	I-P
3	I-P
to	I-P
6	I-P
years	I-P
old	I-P
,	I-P
were	I-P
randomly	I-P
assigned	I-P
to	O
groups	B-I
that	I-I
received	I-I
either	I-I
daily	I-I
sensorimotor	I-I
enrichment	I-I
,	I-I
administered	I-I
by	I-I
their	I-I
parents	I-I
,	I-I
along	I-I
with	I-I
standard	I-I
care	I-I
,	I-I
or	I-I
they	I-I
received	I-I
standard	I-I
care	I-I
alone	I-I
.	I-I


After	O
6	O
months	O
,	O
enriched	O
children	O
showed	O
statistically	O
significant	O
gains	O
in	O
their	O
IQ	B-OUT
scores	I-OUT
,	O
a	O
decline	O
in	O
their	O
atypical	B-OUT
sensory	I-OUT
responses	I-OUT
,	O
and	O
an	O
improvement	O
in	O
their	O
receptive	B-OUT
language	I-OUT
performance	I-OUT
,	O
compared	O
to	O
controls	O
.	O


RESULT	O
(	O
S	O
)	O
No	O
statistically	O
significant	O
difference	O
was	O
detected	O
between	O
the	O
two	O
groups	O
in	O
terms	O
of	O
survival	B-OUT
rate	I-OUT
,	O
but	O
a	O
significantly	O
higher	O
percentage	O
of	O
detectable	B-OUT
spindle	I-OUT
was	O
observed	O
in	O
group	O
B	O
(	O
completely	O
denuded	O
oocytes	O
)	O
,	O
either	O
immediately	O
after	O
warming	O
or	O
3	O
hours	O
after	O
incubation	O
.	O


Racemic	B-I
epinephrine	I-I
has	O
been	O
advocated	O
for	O
the	O
treatment	O
of	O
croup	O
,	O
but	O
controlled	O
studies	O
have	O
not	O
proved	O
it	O
more	O
effective	O
than	O
saline	O
.	O


Twenty	B-P
patients	I-P
(	I-P
aged	I-P
4	I-P
months	I-P
to	I-P
5	I-P
years	I-P
)	I-P
hospitalized	I-P
with	I-P
acute	I-P
croup	I-P
and	I-P
persistent	I-P
inspiratory	I-P
stridor	I-P
at	I-P
rest	I-P
were	O
randomly	O
assigned	O
to	O
one	O
of	O
two	O
treatment	O
groups	O
:	O
saline	B-I
or	I-I
racemic	I-I
epinephrine	I-I
,	O
both	O
nebulized	O
and	O
delivered	O
by	O
intermittent	O
positive	O
pressure	O
breathing	O
.	O


Racemic	B-I
epinephrine	I-I
was	O
significantly	O
more	O
effective	B-OUT
than	O
saline	O
at	O
10	O
(	O
P	O
less	O
than	O
.01	O
)	O
and	O
30	O
minutes	O
(	O
P	O
less	O
than	O
.05	O
)	O
but	O
not	O
at	O
120	O
minutes	O
after	O
the	O
treatment	O
.	O


A	O
double-blind	O
comparison	O
of	O
clomipramine	B-I
,	I-I
desipramine	I-I
,	I-I
and	I-I
placebo	I-I
in	O
the	O
treatment	O
of	O
autistic	B-P
disorder	I-P
.	I-P


DESIGN	O
Following	O
a	O
2-week	O
,	O
single-blind	O
placebo	B-I
washout	O
phase	O
,	O
12	B-P
autistic	I-P
subjects	I-P
completed	O
a	O
10-week	O
,	O
double-blind	O
,	O
crossover	O
comparison	O
of	O
clomipramine	B-I
and	I-I
placebo	I-I
,	O
and	O
12	B-P
different	I-P
subjects	I-P
completed	O
a	O
similar	O
comparison	O
of	O
clomipramine	B-I
and	O
desipramine	B-I
.	I-I


PATIENTS	O
A	B-P
referral	I-P
sample	I-P
of	I-P
30	I-P
male	I-P
and	I-P
female	I-P
autistic	I-P
patients	I-P
were	I-P
enrolled	I-P
,	I-P
and	I-P
24	I-P
completed	I-P
the	I-P
study	I-P
.	I-P


CONCLUSION	O
Biological	O
links	O
between	O
compulsions	O
and	O
stereotyped	O
,	O
repetitive	O
behaviors	O
in	O
autistic	B-P
disorder	I-P
should	O
be	O
explored	O
.	O


OBJECTIVE	O
To	O
compare	O
the	O
effects	O
of	O
a	O
pill	B-I
containing	I-I
drospirenone	I-I
with	I-I
those	I-I
of	I-I
a	I-I
combined	I-I
contraceptive	I-I
vaginal	I-I
ring	I-I
on	I-I
the	O
lipid	O
and	O
carbohydrate	O
metabolism	O
and	O
on	O
the	O
surrogate	O
markers	O
of	O
arterial	O
function	O
.	O


SETTING	O
Bologna	B-P
University	I-P
School	I-P
of	I-P
Medicine	I-P
.	I-P


The	O
6-month	O
treatment	O
with	O
the	O
vaginal	O
ring	O
significantly	O
improved	O
the	O
area	B-OUT
under	I-OUT
the	I-OUT
curve	I-OUT
for	I-OUT
glucose	I-OUT
,	I-OUT
insulin	I-OUT
,	I-OUT
and	I-OUT
C-peptide	I-OUT
,	O
whereas	O
the	O
drospirenone+ethinylestradiol	O
pill	O
induced	O
an	O
increase	O
in	O
the	O
insulinogenic	B-OUT
index	I-OUT
and	O
homeostatic	B-OUT
model	I-OUT
assessment	I-OUT
estimate	I-OUT
for	I-OUT
insulin	I-OUT
resistance	I-OUT
values	I-OUT
.	I-OUT


The	O
number	B-OUT
of	I-OUT
patients	I-OUT
who	I-OUT
needed	I-OUT
a	I-OUT
second	I-OUT
blood	I-OUT
patch	I-OUT
did	O
not	O
differ	O
significantly	O
between	O
the	O
two	O
groups	O
:	O
6	O
(	O
10.0	O
%	O
)	O
for	O
prophylactic	B-I
epidural	I-I
blood	I-I
patch	I-I
and	O
4	O
(	O
11.1	O
%	O
)	O
for	O
therapeutic	B-I
epidural	I-I
blood	I-I
patch	I-I
.	I-I


The	O
effect	O
of	O
acebutolol	B-I
on	O
left	O
ventricular	O
performance	O
was	O
examined	O
by	O
various	O
noninvasive	O
means	O
in	O
three	O
studies	O
.	O


In	O
13	B-P
patients	I-P
with	I-P
stable	I-P
angina	I-P
pectoris	I-P
,	O
single-pass	O
studies	O
of	O
left	O
ventricular	O
function	O
with	O
indium	O
113	O
under	O
double-blind	O
,	O
placebo-controlled	O
conditions	O
similarly	O
showed	O
acebutolol	B-I
to	O
have	O
no	O
clinically	O
significant	O
negative	O
inotropic	O
effects	O
.	O


[	O
Effects	O
of	O
electroacupuncture	B-I
combined	I-I
with	I-I
behavior	I-I
therapy	I-I
on	O
intelligence	O
and	O
behavior	O
of	O
children	B-P
of	I-P
autism	I-P
]	I-P
.	O


METHODS	O
Sixty	B-P
children	I-P
of	I-P
autism	I-P
were	O
randomly	O
divided	O
into	O
an	O
electroacupuncture	B-I
(	I-I
EA	I-I
)	I-I
plus	I-I
behavior	I-I
therapy	I-I
group	I-I
and	I-I
a	I-I
behavior	I-I
therapy	I-I
group	I-I
,	O
30	O
cases	O
in	O
each	O
group	O
.	O


The	O
patients	O
in	O
the	O
two	O
groups	O
were	O
treated	O
with	O
routine	B-I
behavior	I-I
,	O
with	O
EA	B-I
at	O
Baihui	O
(	O
GV	O
20	O
)	O
,	O
Sishencong	O
(	O
EX-HN	O
1	O
)	O
,	O
Shenting	O
(	O
GV	O
24	O
)	O
,	O
Benshen	O
(	O
GB	O
13	O
)	O
,	O
Yintang	O
(	O
EX-HN	O
3	O
)	O
,	O
Naohu	O
(	O
GV	O
17	O
)	O
,	O
Naokong	O
(	O
GB	O
19	O
)	O
,	O
Neiguan	O
(	O
PC	O
6	O
)	O
and	O
scalp	B-I
acupuncture	I-I
at	O
Speech	O
Areas	O
I	O
,	O
II	O
,	O
III	O
added	O
for	O
the	O
EA	B-I
plus	I-I
behavior	I-I
therapy	I-I
group	O
.	O


Their	O
therapeutic	O
effects	O
were	O
observed	O
,	O
and	O
the	O
picture	B-OUT
and	I-OUT
vocabulary	I-OUT
scale	I-OUT
(	I-OUT
PPVT	I-OUT
)	I-OUT
and	O
behavior	B-OUT
ability	I-OUT
were	O
detected	O
.	O


CONCLUSION	O
EA	B-I
combined	I-I
with	I-I
behavior	I-I
therapy	I-I
can	O
significantly	O
improve	O
clinical	O
symptoms	O
of	O
autism	O
,	O
but	O
does	O
not	O
improve	O
intelligence	O
.	O


Clinical	B-I
hypnosis	I-I
versus	I-I
cognitive	I-I
behavioral	I-I
training	I-I
for	O
pain	B-OUT
management	I-OUT
with	O
pediatric	B-P
cancer	I-P
patients	I-P
undergoing	I-P
bone	I-P
marrow	I-P
aspirations	I-P
.	I-P


Patients	O
were	O
randomized	O
to	O
one	O
of	O
three	O
groups	O
:	O
hypnosis	B-I
,	I-I
a	I-I
package	I-I
of	I-I
CB	I-I
coping	I-I
skills	I-I
,	I-I
and	I-I
no	I-I
intervention	I-I
.	I-I


Forty-seven	B-P
children	I-P
were	I-P
randomly	I-P
assigned	I-P
to	I-P
treatment	I-P
and	I-P
wait-list	I-P
control	I-P
groups	I-P
.	I-P


Treatment	O
group	O
children	O
received	O
the	O
parent-delivered	B-I
program	I-I
for	I-I
4	I-I
mo	I-I
.	I-I


Trained	O
therapists	O
provided	O
parent	B-I
training	I-I
and	I-I
support	I-I
.	I-I


Results	O
showed	O
that	O
the	O
parent-delivered	O
program	O
was	O
effective	O
in	O
improving	O
measures	O
of	O
autism	O
(	O
medium	O
effect	O
size	O
)	O
and	O
sensory	B-OUT
and	I-OUT
self-regulatory	I-OUT
responses	I-OUT
(	O
large	O
effect	O
size	O
)	O
.	O


At	O
the	O
end	O
of	O
treatment	O
86	O
%	O
of	O
patients	O
in	O
the	O
CHOP	B-I
arm	O
had	O
responded	O
with	O
58	O
%	O
in	O
CR	O
.	O


Treatment	O
studies	O
document	O
the	O
efficacy	O
of	O
precessation	O
NRT	B-I
and	O
support	O
important	O
roles	O
for	O
level	O
of	O
nicotine	O
dependence	O
and	O
precessation	O
smoking	O
reduction	O
in	O
successful	O
quitting	O
.	O


We	O
now	O
report	O
influences	O
of	O
v1.0	B-OUT
quit-success	I-OUT
genotype	I-OUT
score	I-OUT
,	I-OUT
level	I-OUT
of	I-OUT
dependence	I-OUT
and	I-OUT
precessation	I-OUT
smoking	I-OUT
reduction	I-OUT
in	O
a	O
smoking	O
cessation	O
trial	O
that	O
examined	O
effects	O
of	O
21	O
versus	O
42	O
mg/24	O
h	O
precessation	O
NRT	B-I
.	I-I


Four	B-P
hundred	I-P
seventy-nine	I-P
smokers	I-P
were	O
randomized	O
to	O
21	O
or	O
42	O
mg	O
NRT	B-I
,	O
initiated	O
2	O
wks	O
prior	O
to	O
target	O
quit	O
dates	O
.	O


Genotyping	B-P
used	I-P
Affymetrix	I-OUT
arrays	I-OUT
(	I-P
Santa	I-P
Clara	I-P
,	I-P
CA	I-P
,	I-P
USA	I-P
)	I-P
.	I-P


The	O
primary	O
outcome	O
was	O
10-wk	B-OUT
continuous	I-OUT
smoking	I-OUT
abstinence	I-OUT
.	I-OUT


NRT	B-OUT
dose	I-OUT
,	I-OUT
level	I-OUT
of	I-OUT
nicotine	I-OUT
dependence	I-OUT
and	I-OUT
genotype	I-OUT
scores	I-OUT
displayed	O
significant	B-OUT
interactive	I-OUT
effects	I-OUT
on	O
successful	O
quitting	O
.	O


Successful	B-OUT
abstinence	I-OUT
also	O
was	O
predicted	O
by	O
CO	B-OUT
reductions	I-OUT
during	O
precessation	O
NRT	B-I
.	I-I


Eleven	B-P
healthy	I-P
tobacco	I-P
smoking	I-P
adult	I-P
male	I-P
volunteers	I-P
of	I-P
mixed	I-P
race	I-P
were	O
tobacco	B-I
abstinent	I-I
overnight	O
for	O
this	O
study	O
.	O


Nicotine	B-I
caused	O
a	O
small	O
overall	O
reduction	O
in	O
global	B-OUT
cerebral	I-OUT
metabolism	I-OUT
of	I-OUT
glucose	I-OUT
but	O
,	O
when	O
the	O
data	O
were	O
normalized	O
,	O
several	O
brain	O
regions	O
showed	O
relative	O
increases	B-OUT
in	I-OUT
activity	I-OUT
.	I-OUT


Structures	O
with	O
a	O
decrease	B-OUT
in	I-OUT
regional	I-OUT
cerebral	I-OUT
metabolism	I-OUT
of	I-OUT
glucose	I-OUT
(	I-OUT
pepper	I-OUT
minus	O
nicotine	B-OUT
)	I-OUT
were	O
the	O
left	O
insula	O
and	O
right	O
inferior	O
occipital	O
gyrus	O
,	O
with	O
Z	O
scores	O
>	O
3.5	O
.	O


Study	O
patients	O
were	O
randomized	O
to	O
the	O
two	O
treatment	O
arms	O
,	O
Er	B-I
:	I-I
YAG	I-I
(	O
3.8	O
J/cm	O
(	O
2	O
)	O
,	O
30	O
%	O
pattern	B-I
overlap	I-I
,	O
0	O
%	O
interpulse	B-I
overlap	I-I
,	O
15	O
microm	O
per	O
pass	O
with	O
no	O
coagulation	O
)	O
and	O
IPL	B-I
(	O
560-nm	O
filter	O
,	O
30	O
J/cm	O
(	O
2	O
)	O
,	O
2.4/4.0-ms	O
pulse	O
with	O
10-ms	O
delay	O
)	O
,	O
each	O
receiving	O
three	O
sequential	O
treatments	O
spaced	O
1	O
month	O
apart	O
.	O


Baseline	O
subjective	O
and	O
blinded	B-OUT
physician	I-OUT
dyschromia	I-OUT
and	I-OUT
rhytid	I-OUT
scores	I-OUT
revealed	O
no	O
significant	O
difference	O
between	O
the	O
IPL	O
and	O
Er	O
:	O
YAG	O
randomly	O
assigned	O
sides	O
.	O


Subjective	B-OUT
global	I-OUT
facial	I-OUT
appearance	I-OUT
scores	I-OUT
worsened	O
by	O
5	O
%	O
while	O
blinded	O
physician	O
scores	O
improved	O
by	O
16	O
%	O
3	O
months	O
after	O
3	O
Er	O
:	O
YAG	O
treatments	O
,	O
but	O
by	O
28	O
and	O
20	O
%	O
for	O
IPL	O
,	O
respectively	O
.	O


The	O
overall	B-OUT
incidence	I-OUT
of	I-OUT
adverse	I-OUT
events	I-OUT
and	I-OUT
subsequent	I-OUT
downtime	I-OUT
was	O
increased	O
for	O
Er	O
:	O
YAG	O
(	O
1/10	O
patients	O
experienced	O
hyperpigmentation	B-OUT
,	O
3/10	O
exfoliation	B-OUT
,	O
1/10	O
blistering	B-OUT
,	O
and	O
5/10	O
discomfort	B-OUT
)	I-OUT
compared	O
to	O
IPL	O
(	O
1/10	O
exfoliation	O
and	O
1/10	O
discomfort	O
)	O
,	O
although	O
no	O
permanent	O
side	O
effects	O
were	O
observed	O
with	O
either	O
treatment	O
arm	O
.	O


This	O
study	O
tested	O
the	O
effects	O
of	O
a	O
parent-mediated	B-I
intervention	I-I
on	I-I
parental	I-I
responsiveness	I-I
with	O
their	O
toddlers	B-P
at	I-P
high	I-P
risk	I-P
for	I-P
an	I-P
autism	I-P
spectrum	I-P
disorder	I-P
(	I-P
ASD	I-P
)	I-P
.	I-P


There	O
were	O
no	O
treatment	O
effects	O
on	O
child	B-OUT
outcomes	I-OUT
of	O
joint	B-OUT
attention	I-OUT
or	I-OUT
language	I-OUT
.	I-OUT


Children	O
in	O
both	O
groups	O
made	O
significant	O
developmental	O
gains	O
in	O
cognition	B-OUT
and	I-OUT
language	I-OUT
skills	I-OUT
over	O
one	O
year	O
.	O


These	O
results	O
support	O
parental	B-I
responsiveness	I-I
as	O
an	O
important	O
intervention	O
target	O
given	O
its	O
general	O
association	O
with	O
child	O
outcomes	O
in	O
the	O
extant	O
literature	O
;	O
however	O
,	O
additional	O
supports	O
are	O
likely	O
needed	O
to	O
fully	O
maintain	O
the	O
treatment	O
effect	O
and	O
to	O
affect	O
child	O
outcomes	O
.	O


Pharmacologic	O
treatment	O
is	O
usually	O
begun	O
with	O
nonopioid	O
analgesics	O
,	O
most	O
frequently	O
acetaminophen	B-I
.	I-I


If	O
pain	B-OUT
relief	I-OUT
is	O
not	O
achieved	O
,	O
the	O
so-called	O
"	O
weak	O
"	O
opioids	O
,	O
such	O
as	O
codeine	B-I
and	I-I
hydrocodone	I-I
,	O
may	O
be	O
used	O
in	B-I
combination	I-I
with	I-I
acetaminophen	I-I
.	I-I


OBJECTIVE	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
analgesic	B-OUT
efficacy	I-OUT
and	I-OUT
tolerability	I-OUT
of	O
codeine	B-I
phosphate	I-I
versus	I-I
hydrocodone	I-I
bitartrate	I-I
in	O
combination	O
with	O
acetaminophen	B-I
in	O
the	O
relief	O
of	O
cancer-related	O
pain	O
.	O


Outpatients	B-P
with	I-P
cancer	I-P
were	I-P
eligible	I-P
for	I-P
the	I-P
study	I-P
if	I-P
they	I-P
were	I-P
aged	I-P
>	I-P
-18	I-P
years	I-P
and	I-P
had	I-P
chronic	I-P
(	I-P
duration	I-P
,	I-P
>	I-P
/=	I-P
3	I-P
months	I-P
)	I-P
moderate	I-P
to	I-P
severe	I-P
cancer-related	I-P
pain	I-P
(	I-P
score	I-P
on	I-P
10-cm	I-P
visual	I-P
analog	I-P
scale	I-P
[	I-P
VAS	I-P
]	I-P
,	I-P
>	I-P
3	I-P
cm	I-P
[	I-P
moderate	I-P
]	I-P
;	I-P
score	I-P
on	I-P
a	I-P
4-point	I-P
verbal	I-P
pain-intensity	I-P
scale	I-P
,	I-P
>	I-P
1	I-P
[	I-P
moderate	I-P
]	I-P
)	I-P
.	I-P


Eligible	O
patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
1	O
tablet	O
of	B-I
codeine/acetaminophen	I-I
(	I-I
C/A	I-I
)	I-I
30/500	O
mg	O
or	B-I
hydrocodone/acetaminophen	I-I
(	I-I
H/A	I-I
)	I-I
5/500	O
mg	O
PO	O
q4h	O
(	O
total	O
daily	O
doses	O
,	O
150/2500	O
and	O
25/2500	O
mg	O
,	O
respectively	O
)	O
for	O
23	O
days	O
.	O


The	O
primary	O
end	O
point	O
was	O
the	B-OUT
proportion	I-OUT
of	I-OUT
patients	I-OUT
who	I-OUT
achieved	I-OUT
pain	I-OUT
relief	I-OUT
(	O
defined	O
as	O
a	O
score	O
of	O
>	O
1	O
on	O
a	O
5-point	O
verbal	O
rating	O
scale	O
[	O
VRS	O
]	O
(	O
0	O
=	O
none	O
;	O
1	O
=	O
a	O
little	O
;	O
2	O
=	O
some	O
;	O
3	O
=	O
a	O
lot	O
;	O
and	O
4	O
=	O
complete	O
)	O
on	O
study	O
days	O
1	O
and	O
2	O
and	O
weeks	O
1	O
,	O
2	O
,	O
and	O
3	O
.	O


The	O
secondary	O
end	O
point	O
was	O
the	B-OUT
proportion	I-OUT
of	I-OUT
patients	I-OUT
in	I-OUT
whom	I-OUT
pain	I-OUT
was	I-OUT
decreased	I-OUT
(	O
VAS	O
score	O
,	O
<	O
-	O
3	O
cm	O
)	O
.	O


Of	B-P
the	I-OUT
total	I-OUT
number	I-OUT
of	I-OUT
cases	I-OUT
,	I-P
59	I-P
%	I-P
were	I-P
aged	I-P
60	I-P
to	I-P
89	I-P
years	I-P
,	I-P
and	I-P
55	I-P
%	I-P
were	I-P
men	I-P
.	O


The	O
most	O
common	O
AEs	O
in	O
the	B-I
C/A	I-I
and	I-I
H/A	I-I
groups	O
were	B-OUT
constipation	I-OUT
(	O
36	O
%	O
and	O
29	O
%	O
,	O
respectively	O
)	O
,	O
dizziness	B-OUT
(	O
24	O
%	O
and	O
19	O
%	O
)	O
,	O
vomiting	B-OUT
(	O
24	O
%	O
and	O
16	O
%	O
)	O
,	O
and	B-OUT
dry	I-OUT
mouth	I-OUT
(	O
15	O
%	O
and	O
18	O
%	O
)	O
,	O
with	O
no	O
significant	O
differences	O
between	O
groups	O
.	O


MF101	B-I
,	I-I
a	I-I
selective	I-I
estrogen	I-I
receptor	I-I
beta	O
modulator	O
for	O
the	O
treatment	O
of	O
menopausal	O
hot	O
flushes	O
:	O
a	O
phase	O
II	O
clinical	O
trial	O
.	O


After	O
12	O
weeks	O
,	O
the	O
mean	B-OUT
percent	I-OUT
decrease	I-OUT
in	I-OUT
frequency	I-OUT
of	I-OUT
hot	I-OUT
flushes	I-OUT
in	O
the	O
10	O
g/day	O
group	O
was	O
12.9	O
%	O
greater	O
than	O
that	O
in	O
the	O
placebo	B-I
group	O
(	O
P	O
=	O
0.15	O
)	O
,	O
the	O
median	O
percent	O
decrease	O
was	O
11.7	O
%	O
greater	O
than	O
that	O
in	O
the	O
placebo	O
group	O
(	O
P	O
=	O
0.05	O
)	O
,	O
and	O
the	O
proportion	B-OUT
of	I-OUT
women	I-OUT
with	I-OUT
at	I-OUT
least	I-OUT
a	I-OUT
50	I-OUT
%	I-OUT
reduction	I-OUT
in	I-OUT
hot	I-OUT
flushes	I-OUT
was	O
16.2	O
%	O
greater	O
than	O
that	O
in	O
the	O
placebo	O
group	O
(	O
P	O
=	O
0.03	O
)	O
.	O


CONCLUSIONS	O
Treatment	O
with	O
10	O
g/day	O
of	O
MF101	B-I
reduces	O
the	O
frequency	O
of	O
hot	O
flushes	O
.	O


The	O
effect	O
of	O
a	O
combined	O
intervention	O
including	O
MP	O
plus	O
a	O
nursing	B-I
telephone	I-I
intervention	I-I
(	I-I
NTI	I-I
)	I-I
was	O
also	O
assessed	O
.	O


Median	B-OUT
FACIT-F	I-OUT
fatigue	I-OUT
scores	I-OUT
improved	O
from	O
baseline	O
to	O
day	O
15	O
in	O
all	O
groups	O
:	O
MP+NTI	O
(	O
median	O
score	O
,	O
4.5	O
;	O
P	O
=	O
.005	O
)	O
,	O
PL+NTI	O
(	O
median	O
score	O
,	O
8.0	O
;	O
P	O
<	O
.001	O
)	O
,	O
MP+CTI	O
(	O
median	O
score	O
,	O
7.0	O
;	O
P	O
=	O
.004	O
)	O
,	O
and	O
PL+CTI	O
(	O
median	O
score	O
,	O
5.0	O
;	O
P	O
=	O
.03	O
)	O
.	O


However	O
,	O
there	O
were	O
no	O
significant	O
differences	O
in	O
the	O
median	O
improvement	O
in	B-OUT
FACIT-F	I-OUT
fatigue	I-OUT
between	O
the	O
MP	O
and	O
PL	O
groups	O
(	O
5.5	O
v	O
6.0	O
,	O
respectively	O
;	O
P	O
=	O
.69	O
)	O
and	O
among	O
all	O
four	O
groups	O
(	O
P	O
=	O
.16	B-OUT
)	I-OUT
.	I-OUT


Fatigue	B-OUT
(	O
P	O
<	O
.001	B-OUT
)	I-OUT
,	I-OUT
nausea	I-OUT
(	O
P	O
=	O
.01	B-OUT
)	I-OUT
,	I-OUT
depression	I-OUT
(	O
P	O
=	O
.02	B-OUT
)	I-OUT
,	I-OUT
anxiety	I-OUT
(	O
P	O
=	O
.01	B-OUT
)	I-OUT
,	I-OUT
drowsiness	I-OUT
(	O
P	O
<	O
.001	B-OUT
)	I-OUT
,	I-OUT
appetite	I-OUT
(	O
P	O
=	O
.009	B-OUT
)	I-OUT
,	I-OUT
sleep	I-OUT
(	O
P	O
<	O
.001	O
)	O
,	O
and	B-OUT
feeling	I-OUT
of	I-OUT
well-being	I-OUT
(	O
P	O
<	O
.001	O
)	O
,	O
as	O
measured	O
by	O
the	O
ESAS	O
,	O
significantly	O
improved	O
in	O
patients	O
who	O
received	O
NTI	B-OUT
.	I-OUT


CONCLUSION	O
MP	O
and	O
NTI	O
alone	O
or	O
combined	O
were	O
not	O
superior	B-I
to	I-I
placebo	I-I
in	O
improving	B-OUT
CRF	O
.	O


The	O
effect	O
of	O
the	O
video	B-I
game	I-I
Mindlight	I-I
on	O
anxiety	B-OUT
symptoms	I-OUT
in	O
children	B-P
with	I-P
an	I-P
Autism	I-P
Spectrum	I-P
Disorder	I-P
.	I-P


BACKGROUND	O
In	O
the	O
clinical	O
setting	O
,	O
a	O
large	O
proportion	O
of	O
children	B-P
with	I-P
an	I-P
autism	I-P
spectrum	I-P
disorder	I-P
(	I-P
ASD	I-P
)	I-P
experience	I-P
anxiety	I-OUT
symptoms	I-OUT
.	I-OUT


This	O
approach	O
is	O
based	O
on	O
recent	O
research	O
suggesting	O
that	O
video	B-I
games	I-I
might	O
be	O
suitable	O
as	O
an	O
intervention	O
vehicle	O
to	O
enhance	O
mental	O
health	O
in	O
children	O
.	O


It	O
is	O
expected	O
that	O
children	O
in	O
the	O
experimental	O
condition	O
will	O
show	O
lower	O
levels	O
of	O
anxiety	B-OUT
symptoms	I-OUT
at	O
3-months	O
follow-up	O
,	O
compared	O
to	O
children	O
in	O
the	O
control	O
condition	O
.	O


[	B-OUT
Acute	I-OUT
cardiovascular	I-OUT
and	I-OUT
metabolic	I-OUT
changes	I-OUT
in	O
interval	O
and	O
endurance	B-I
training	I-I
in	O
selected	B-P
patients	I-P
following	I-P
aortocoronary	I-P
bypass	I-P
operation	I-P
]	I-P
.	O


UNLABELLED	O
This	O
study	O
compared	O
the	O
acute	B-OUT
changes	I-OUT
of	I-OUT
cardiovascular	I-OUT
and	I-OUT
metabolic	I-OUT
reactions	I-OUT
during	O
interval	B-I
and	I-I
continuous	I-I
training	I-I
after	O
coronary	O
bypass	O
surgery	O
.	O


)	B-P
each	I-I
trained	I-I
on	I-I
bicycle	I-I
ergometer	I-I
start	I-I
on	I-I
post-operative	I-I
days	I-I
24	I-I
and	I-I
26	I-I
,	I-I
resp	I-I
.	I-I


In	B-I
the	I-I
last	I-I
week	I-I
of	I-I
training	I-I
the	I-I
exercise	I-I
intensity	I-I
in	I-I
the	I-I
group	I-I
of	I-I
patients	I-I
who	I-I
were	I-I
trained	I-I
by	I-I
the	I-I
continuous	I-I
method	I-I
was	I-I
at	I-I
83	I-I
watts	I-I
,	I-I
and	I-I
at	I-I
20:121	I-I
watts	I-I
in	I-I
the	I-I
group	I-I
of	I-I
patients	I-I
who	I-I
were	I-I
trained	I-I
by	I-I
interval	I-I
method	I-I
(	I-I
rest	I-I
:	I-I
work	I-I
each	I-I
1:1	I-I
min	I-I
)	I-I
.	I-I


RESULTS	O
In	O
both	O
methods	O
there	O
were	O
no	B-OUT
significant	I-OUT
differences	I-OUT
in	I-OUT
systolic	I-OUT
and	I-OUT
diastolic	I-OUT
pressure	I-OUT
,	I-OUT
rate-pressure	I-OUT
product	I-OUT
,	I-OUT
in	I-OUT
glucose	I-OUT
or	I-OUT
catecholamine	I-OUT
levels	I-OUT
.	I-OUT


Moderate-intensity	B-I
exercise	I-I
training	I-I
with	O
elements	O
of	O
step	O
aerobics	O
in	O
patients	B-P
with	I-P
severe	I-P
chronic	I-P
heart	I-P
failure	I-P
.	I-P


OBJECTIVE	O
To	O
evaluate	O
whether	O
a	O
specific	O
program	O
of	O
moderate-intensity	B-I
step	I-I
aerobics	I-I
training	I-I
may	O
be	O
sufficient	O
to	O
improve	O
the	O
exercise	O
tolerance	O
of	O
patients	B-P
with	I-P
severe	I-P
chronic	I-P
heart	I-P
failure	I-P
.	I-P


The	O
control	O
group	O
did	O
not	O
perform	B-I
a	I-I
training	I-I
program	I-I
.	I-I


MAIN	O
OUTCOME	O
MEASURES	O
Peak	B-OUT
oxygen	I-OUT
uptake	I-OUT
,	I-OUT
peak	I-OUT
workload	I-OUT
,	I-OUT
percent	I-OUT
of	I-OUT
predicted	I-OUT
power	I-OUT
ability	I-OUT
.	I-OUT


RESULTS	O
Significant	O
increases	O
in	O
peak	B-OUT
oxygen	I-OUT
uptake	I-OUT
(	O
15	O
+/-	O
3.4	O
to	O
18.5	O
+/-	O
2.9mL/kg/min	O
;	O
p	O
=	O
.001	O
)	O
,	O
peak	B-OUT
workload	I-OUT
(	O
77	O
+/-	O
26	O
to	O
99	O
+/-	O
31	O
watts	O
;	O
p	O
=	O
.000	O
)	O
,	O
and	O
percent	B-OUT
of	I-OUT
predicted	I-OUT
power	I-OUT
ability	I-OUT
(	O
43	O
%	O
+/-	O
10	O
%	O
to	O
56	O
%	O
+/-	O
13	O
%	O
;	O
p	O
=	O
.000	O
)	O
were	O
observed	O
in	O
the	O
exercise	O
group	O
.	O


There	O
were	O
no	O
critical	O
changes	O
in	O
heart	B-OUT
rate	I-OUT
or	I-OUT
blood	I-OUT
pressure	I-OUT
in	O
either	O
group	O
.	O


Following	O
priming	O
,	O
an	O
automatic	O
imitation	O
paradigm	O
was	O
used	O
to	O
acquire	O
an	O
index	B-OUT
of	I-OUT
imitation	I-OUT
.	I-OUT


Whereas	O
imitation	B-OUT
levels	I-OUT
were	O
higher	O
for	O
pro-socially	O
primed	O
relative	O
to	O
non-socially	O
primed	O
control	B-P
participants	I-P
,	O
there	O
was	O
no	O
difference	O
between	O
pro-	O
and	O
non-	O
socially	O
primed	O
individuals	B-P
with	I-P
ASC	I-P
.	I-P


We	O
conclude	O
that	O
high-functioning	B-P
adults	I-P
with	I-P
ASC	I-P
demonstrate	O
atypical	B-OUT
social	I-OUT
modulation	I-OUT
of	I-OUT
imitation	I-OUT
.	I-OUT


A	O
limited	O
sampling	O
model	O
has	O
been	O
developed	O
for	O
flunarizine	O
following	O
a	O
30	O
mg	O
oral	O
dose	O
in	O
epileptic	B-P
patients	I-P
who	I-P
were	I-I
receiving	I-I
phenytoin	I-I
or	I-I
carbamazepine	I-I
or	I-I
both	I-I
,	I-I
to	I-I
estimate	I-OUT
the	I-OUT
area	I-OUT
under	I-OUT
the	I-OUT
curve	I-OUT
(	I-OUT
AUC	I-OUT
)	I-OUT
and	I-OUT
maximum	I-OUT
plasma	I-OUT
concentration	I-OUT
(	I-OUT
Cmax	I-OUT
)	I-OUT
.	I-OUT


The	O
model	O
was	O
developed	O
using	O
training	O
data	O
sets	O
from	O
30	B-P
,	I-P
20	I-P
,	I-P
15	I-P
,	I-P
or	I-P
10	I-P
patients	I-P
at	I-P
one	I-P
or	I-P
two	I-P
time	I-P
points	I-P
.	I-P


The	O
model	O
provided	O
reasonably	O
good	O
estimates	B-OUT
for	I-OUT
both	I-OUT
AUC	I-OUT
and	I-OUT
Cmax	I-OUT
.	I-OUT


The	O
bias	B-OUT
of	I-OUT
the	I-OUT
prediction	I-OUT
was	O
2	O
%	O
and	O
precision	O
was	O
28	O
%	O
.	O


The	O
mean	O
predicted	B-OUT
Cmax	I-OUT
of	I-OUT
flunarizine	I-OUT
was	O
86	O
+/-	O
32	O
ng	O
mL-1	O
as	O
compared	O
to	O
an	O
observed	B-OUT
mean	I-OUT
Cmax	I-OUT
of	O
90	O
+/-	O
42	O
ng	O
mL-1	O
.	O


Naltrexone	B-I
in	O
young	B-P
autistic	I-P
children	I-P
:	I-P
a	O
double-blind	O
,	O
placebo-controlled	B-I
crossover	O
study	O
.	O


OBJECTIVE	O
This	O
study	O
evaluated	O
the	O
efficacy	B-OUT
and	I-OUT
safety	I-OUT
of	O
naltrexone	B-I
,	O
an	O
opiate	O
blocker	O
,	O
in	O
the	O
treatment	O
of	O
autism	B-P
.	I-P


Dependent	B-I
measures	I-I
included	I-I
parent	I-I
and	I-I
teacher	I-I
Clinical	I-OUT
Global	I-OUT
Impressions	I-OUT
(	I-OUT
CGI	I-OUT
)	I-OUT
,	I-OUT
Conners	I-OUT
Rating	I-OUT
Scales	I-OUT
,	I-OUT
and	I-OUT
Naltrexone	I-OUT
Side-Effects	I-OUT
(	I-OUT
SE	I-OUT
)	I-OUT
Rating	I-OUT
Scale	I-OUT
;	I-OUT
laboratory	I-OUT
CGI	I-OUT
,	I-OUT
movement	I-OUT
actometer	I-OUT
readings	I-OUT
,	I-OUT
and	I-OUT
a	I-OUT
10-second	I-OUT
interval	I-OUT
recording	I-OUT
system	I-OUT
analysis	I-OUT
of	I-OUT
on-task	I-OUT
,	I-OUT
communication	I-OUT
initiations	I-OUT
,	I-OUT
disruptive	I-OUT
behavior	I-OUT
,	I-OUT
and	I-OUT
self-stimulation	I-OUT
.	I-OUT


Adverse	B-OUT
side	I-OUT
effects	I-OUT
were	O
behavioral	O
,	O
mild	O
,	O
and	O
transient	O
.	O


Frequent	O
treatment-emergent	O
grade	O
3/4	O
hematologic	B-OUT
abnormalities	I-OUT
were	O
lymphopenia	B-OUT
(	O
20	O
%	O
v	O
11	O
%	O
)	O
,	O
anemia	B-OUT
(	O
9	O
%	O
v	O
8	O
%	O
)	O
,	O
and	O
neutropenia	B-OUT
(	O
6	O
%	O
v	O
<	O
1	O
%	O
)	O
.	O


RESULTS	O
all-E-Zeaxanthin	B-OUT
concentrations	I-OUT
increased	O
from	O
0.048	O
+/-	O
0.026	O
micro	O
mol/L	O
at	O
baseline	O
to	O
0.20	O
+/-	O
0.07	O
and	O
0.92	O
+/-	O
0.28	O
micro	O
mol/L	O
with	O
1	O
and	O
10	O
mg	O
zeaxanthin	B-I
,	O
respectively	O
.	O


The	O
dose-normalized	B-OUT
bioavailability	I-OUT
of	I-OUT
all-E-zeaxanthin	I-OUT
after	O
the10-mg	O
dose	O
was	O
40	O
%	O
lower	O
(	O
P	O
<	O
0.001	O
)	O
than	O
after	O
the	O
1-mg	O
dose	O
.	O


Other	O
kinetic	B-OUT
parameters	I-OUT
did	O
not	O
differ	O
significantly	O
between	O
groups	O
.	O


The	O
time	B-OUT
course	I-OUT
of	I-OUT
plasma	I-OUT
all-E-3-'dehydro-lutein	I-OUT
concentrations	I-OUT
resembled	O
that	O
of	O
all-E-zeaxanthin	B-I
.	I-I


Concentrations	B-OUT
of	I-OUT
other	I-OUT
carotenoids	I-OUT
were	O
not	O
affected	O
.	O


AIMS	O
We	O
therefore	O
used	O
functional	B-I
magnetic	I-I
resonance	I-I
imaging	I-I
(	O
fMRI	O
)	O
to	O
investigate	O
the	O
so	O
far	O
unknown	O
shared	O
and	O
disorder-specific	O
inhibitory	B-OUT
brain	I-OUT
dysfunctions	I-OUT
in	O
these	O
two	O
disorders	O
,	O
as	O
well	O
as	O
the	O
effects	O
of	O
a	O
single	O
dose	O
of	O
the	O
selective	O
serotonin	O
reuptake	O
inhibitor	O
fluoxetine	O
.	O


Repeated	O
measures	O
analyses	O
within	O
patients	O
assessed	O
drug	B-OUT
effects	I-OUT
.	I-OUT


CONCLUSIONS	O
The	O
findings	O
show	O
that	O
fluoxetine	O
normalises	O
frontal	B-OUT
lobe	I-OUT
dysfunctions	I-OUT
in	O
both	O
disorders	O
via	O
inverse	O
effects	O
,	O
downregulating	O
abnormally	O
increased	O
frontal	B-OUT
activation	I-OUT
in	O
ASD	O
and	O
upregulating	O
abnormally	O
decreased	O
frontal	B-OUT
activation	I-OUT
in	O
ADHD	O
,	O
potentially	O
reflecting	O
inverse	O
baseline	O
serotonin	O
levels	O
in	O
both	O
disorders	O
.	O


A	O
randomized	O
trial	O
of	O
immunotherapy	B-I
for	O
persistent	B-P
genital	I-P
warts	I-P
.	I-P


RESULTS	O
Of	B-P
33	I-P
protocol	I-P
compliant	I-P
Brisbane	I-P
recipients	I-P
of	I-P
placebo	I-P
immunotherapy	I-P
,	O
11	O
were	O
disease	O
free	O
at	O
two	O
months	O
,	O
and	O
a	O
further	O
9	O
demonstrated	O
reduction	O
of	O
>	O
50	O
%	O
in	B-OUT
total	I-OUT
wart	I-OUT
area	I-OUT
.	I-OUT


Wart	B-OUT
area	I-OUT
reduction	I-OUT
following	O
destructive	O
treatment	O
correlated	O
with	O
prior	O
duration	O
of	O
disease	O
.	O


Prior	B-OUT
disease	I-OUT
duration	O
was	O
much	O
shorter	O
in	O
Wenzhou	O
subject	O
(	O
8.1	O
±	O
1.1	O
mo	O
)	O
than	O
in	O
Brisbane	O
subjects	O
(	O
53.7	O
±	O
5.5	O
mo	O
)	O
.	O


No	O
significant	O
reduction	B-OUT
in	I-OUT
mean	I-OUT
wart	O
area	O
was	O
observed	B-P
for	I-P
the	I-P
168	I-P
Wenzhou	I-P
protocol	I-P
compliant	I-P
subjects	I-P
who	I-P
also	I-P
received	I-P
VLP	I-P
immunotherapy	I-P
.	O


CONCLUSIONS	O
This	O
study	O
confirms	O
the	O
findings	O
in	O
a	O
previous	O
open	O
label	O
trial	O
that	O
administration	O
of	O
VLP	O
immunotherapy	O
may	O
assist	O
in	O
clearance	O
of	B-OUT
recurrent	I-OUT
genital	I-OUT
warts	I-P
in	I-P
patients	I-P
for	I-P
whom	I-P
destructive	I-P
therapy	I-P
is	I-P
unsuccessful	I-P
and	O
that	O
unsuccessful	O
destructive	O
therapy	O
is	O
more	O
common	O
with	O
increasing	O
prior	O
disease	O
duration	O
.	O


The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
effect	O
of	O
extracorporeal	B-I
shock	I-I
wave	I-I
therapy	I-I
(	O
ESWT	O
)	O
in	O
patients	O
with	O
chronically	B-P
painful	I-P
proximal	I-P
plantar	I-P
fasciitis	I-P
with	O
a	O
further	O
conventional	O
conservative	O
treatment	O
.	O


Forty-seven	B-P
patients	I-P
(	I-P
49	I-P
feet	I-P
)	I-P
with	I-P
a	I-P
previously	I-P
unsuccessful	I-P
nonsurgical	I-P
treatment	I-P
of	I-P
at	I-P
least	I-P
6	I-P
months	I-P
were	I-P
randomized	I-P
to	I-P
two	I-P
groups	I-P
.	I-P


Heel	B-I
cups	I-I
had	O
to	O
be	O
worn	O
throughout	O
the	O
study	O
.	O


At	O
12	O
weeks	O
after	O
ESWT	O
,	O
the	O
pain	B-OUT
estimation	I-OUT
on	I-OUT
the	I-OUT
visual	I-OUT
analogue	I-OUT
scale	I-OUT
(	I-OUT
VAS	I-OUT
)	I-OUT
for	I-OUT
activities	I-OUT
of	I-OUT
daily	I-OUT
living	I-OUT
diminished	O
significantly	O
by	O
62.9	O
%	O
in	O
group	O
1	O
and	O
by	O
63.0	O
%	O
in	O
group	O
2	O
.	O


The	O
comfortable	B-OUT
walking	I-OUT
time	I-OUT
had	O
increased	O
significantly	O
in	O
both	O
groups	O
.	O


A	O
pilot	O
study	O
on	O
the	O
efficacy	O
of	O
melodic	B-I
based	I-I
communication	I-I
therapy	I-I
for	O
eliciting	B-OUT
speech	I-OUT
in	O
nonverbal	B-P
children	I-P
with	I-P
autism	I-P
.	I-P


The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
efficacy	O
of	O
melodic	B-I
based	I-I
communication	I-I
therapy	I-I
(	I-I
MBCT	I-I
)	I-I
to	I-I
traditional	I-I
speech	I-I
and	I-I
language	I-I
therapy	I-I
for	O
eliciting	B-OUT
speech	I-OUT
in	O
nonverbal	B-P
children	I-P
with	I-P
autism	I-P
.	I-P


The	O
MBCT	O
group	O
progressed	O
significantly	O
in	O
number	B-OUT
of	I-OUT
verbal	I-OUT
attempts	I-OUT
after	O
weeks	O
1	O
through	O
4	O
and	O
number	B-OUT
of	I-OUT
correct	I-OUT
words	I-OUT
after	O
weeks	O
1	O
and	O
3	O
,	O
while	O
the	O
traditional	O
group	O
progressed	O
significantly	O
after	O
weeks	O
4	O
and	O
5	O
.	O


No	O
significant	O
differences	O
in	O
number	B-OUT
of	I-OUT
verbal	I-OUT
attempts	I-OUT
or	I-OUT
number	I-OUT
of	I-OUT
correct	I-OUT
words	I-OUT
were	O
noted	O
between	O
groups	O
following	O
treatment	O
.	O


The	O
repeat	B-OUT
pregnancy	I-OUT
rate	I-OUT
in	O
the	O
experimental	O
group	O
was	O
12	O
%	O
after	O
18	O
months	O
,	O
and	O
28	O
%	O
in	O
the	O
control	O
group	O
.	O


After	O
12	O
months	O
,	O
the	O
infants	O
in	O
the	O
experimental	O
group	O
were	O
more	O
likely	O
to	O
be	O
fully	B-OUT
immunized	I-OUT
(	O
33	O
%	O
)	O
than	O
the	O
infants	O
in	O
the	O
control	O
group	O
(	O
18	O
%	O
)	O
.	O


Outcome	B-OUT
of	O
children	B-P
with	I-P
centrally	I-P
reviewed	I-P
low-grade	I-P
gliomas	I-P
treated	I-P
with	I-P
chemotherapy	I-I
with	I-I
or	I-I
without	I-I
radiotherapy	I-I
on	O
Children	O
's	O
Cancer	O
Group	O
high-grade	O
glioma	O
study	O
CCG-945	O
.	O


BACKGROUND	O
The	O
objectives	O
of	O
the	O
current	O
study	O
were	O
to	O
determine	O
the	O
outcome	B-OUT
of	O
children	B-P
who	I-P
were	I-P
treated	I-P
with	I-P
chemotherapy	I-I
and	I-I
radiotherapy	I-I
on	I-P
the	I-P
Children	I-P
's	I-P
Cancer	I-P
Group	I-P
(	I-P
CCG	I-P
)	I-P
high-grade	I-P
glioma	I-P
protocol	I-P
(	I-P
CCG-945	I-P
)	I-P
who	I-P
were	I-P
diagnosed	I-P
with	I-P
low-grade	I-P
gliomas	I-P
on	I-P
post	I-P
hoc	I-P
central	I-P
pathologic	I-P
review	I-P
and	O
to	O
identify	O
clinical	B-OUT
and	I-OUT
biologic	I-OUT
features	I-OUT
associated	O
with	O
prognosis	O
.	O


METHODS	O
Between	B-P
1985	I-P
and	I-P
1991	I-P
,	I-P
250	I-P
children	I-P
with	I-P
institutionally	I-P
classified	I-P
high-grade	I-P
gliomas	I-P
were	I-P
enrolled	I-P
on	I-P
CCG-945	I-P
.	I-P


Central	O
independent	O
review	O
by	O
5	O
neuropathologists	O
led	O
to	O
a	O
reclassification	O
of	O
low-grade	B-P
glioma	I-P
in	I-P
70	I-P
patients	I-P
,	I-P
who	I-P
were	I-P
the	I-P
focus	I-P
of	I-P
the	I-P
current	I-P
study	I-P
.	I-P


RESULTS	O
The	O
study	O
involved	O
42	B-P
males	I-P
and	I-P
28	I-P
females	I-P
(	I-P
median	I-P
age	I-P
,	I-P
7.7	I-P
years	I-P
)	I-P
with	I-P
a	I-P
median	I-P
follow-up	I-P
of	I-P
10.4	I-P
years	I-P
.	I-P


CONCLUSIONS	O
The	O
current	O
report	O
calls	O
attention	O
to	O
the	O
importance	O
of	O
central	O
pathologic	O
review	O
in	O
large	O
multiinstitutional	O
trials	O
of	O
children	O
with	O
gliomas	O
and	O
suggests	O
that	O
aggressive	O
front-line	O
combined	O
chemoradiotherapy	O
does	O
not	O
confer	O
a	O
survival	B-OUT
advantage	I-OUT
in	O
this	O
highly	O
selected	O
population	O
of	O
patients	O
.	O


Dalteparin	B-I
low	O
molecular	O
weight	O
heparin	B-I
(	O
LMWH	O
)	O
in	O
ovarian	B-P
cancer	I-P
:	I-P
a	O
phase	O
II	O
randomized	O
study	O
.	O


A	O
multicentre	O
phase	O
II	O
randomized	O
trial	O
was	O
done	O
to	O
evaluate	O
the	O
antineoplastic	O
potential	O
of	O
dalteparin	B-I
in	O
ovarian	O
cancer	O
(	O
OC	O
)	O
.	O


MATERIALS	O
AND	O
METHODS	O
Women	B-P
with	I-P
newly-diagnosed	I-P
epithelial	I-P
OC	I-P
were	O
randomized	O
to	O
receive	O
standard	B-I
chemotherapy	I-I
(	I-I
CT	I-I
)	I-I
and	O
one	O
of	O
3	O
doses	O
of	O
dalteparin	B-I
(	O
50	O
IU/kg	O
,	O
100	O
IU/kg	O
,	O
or	O
150	O
IU/kg	O
)	O
subcutaneously	O
once	O
daily	O
during	O
the	O
first	O
3	O
of	O
6	O
cycles	O
of	O
3-weekly	O
CT	O
.	O


The	O
primary	O
outcome	O
was	O
tumor	B-OUT
response	I-OUT
defined	I-OUT
by	I-OUT
≥	I-OUT
50	I-OUT
%	I-OUT
reduction	I-OUT
in	I-OUT
serum	I-OUT
CA125	I-OUT
from	I-OUT
baseline	I-OUT
sustained	I-OUT
for	I-OUT
at	I-OUT
least	I-OUT
28	I-OUT
days	I-OUT
.	O


A	O
50	O
%	O
drop	O
in	B-OUT
CA125	I-OUT
at	O
the	O
end	O
of	O
cycle	O
3	O
was	O
seen	O
in	O
85	O
%	O
of	O
the	O
50	O
IU/kg	O
group	O
,	O
92	O
%	O
of	O
the	O
100	O
IU/kg	O
group	O
,	O
and	O
85	O
%	O
of	O
the	O
150	O
IU/kg	O
group	O
.	O


There	O
were	O
no	B-OUT
symptomatic	I-OUT
VTE	I-OUT
or	I-OUT
major	I-OUT
bleeding	I-OUT
events	I-OUT
while	O
on	O
dalteparin	O
.	O


Women	O
on	O
dalteparin	O
had	O
lower	O
levels	O
of	B-OUT
D-dimer	I-OUT
and	I-OUT
thrombin-antithrombin	I-OUT
,	I-OUT
and	I-OUT
higher	I-OUT
levels	I-OUT
of	I-OUT
tissue	I-OUT
factor	I-OUT
pathway	I-OUT
inhibitor	I-OUT
,	O
relative	O
to	O
baseline	O
.	O


CONCLUSION	B-I
Dalteparin	I-I
is	I-OUT
safe	I-OUT
and	O
well	B-OUT
tolerated	I-OUT
in	I-P
women	I-P
receiving	I-P
CT	I-P
for	I-P
newly-diagnosed	I-P
epithelial	I-P
OC	I-P
.	O


Interferential	B-I
therapy	I-I
electrode	I-I
placement	I-I
technique	I-I
in	O
acute	B-P
low	I-P
back	I-P
pain	I-P
:	I-P
a	O
preliminary	O
investigation	O
.	O


PATIENTS	O
A	O
random	O
sample	O
of	O
60	B-P
eligible	I-P
patients	I-P
with	I-P
back	I-P
pain	I-P
(	I-P
28	I-P
men	I-P
,	I-P
32	I-P
women	I-P
)	I-P
were	I-P
recruited	I-P
by	I-P
general	I-P
practitioners	I-P
and	I-P
self-referral	I-P
for	O
physiotherapy	O
treatment	O
and	O
randomly	O
assigned	O
to	O
1	O
of	O
3	O
groups	O
.	O


INTERVENTIONS	O
(	O
1	O
)	O
"	B-I
IFT	I-I
painful	I-I
area	I-I
"	I-I
and	I-I
The	I-I
Back	I-I
Book	I-I
,	O
(	O
2	O
)	O
"	B-I
IFT	I-I
spinal	I-I
nerve	I-I
"	I-I
and	I-I
The	I-I
Back	I-I
Book	I-I
,	O
and	O
(	O
3	O
)	O
"	B-I
Control	I-I
,	I-I
"	I-I
The	I-I
Back	I-I
Book	I-I
only	O
.	O


Standardized	O
IFT	B-I
stimulation	O
parameters	O
were	O
used	O
:	O
carrier	O
frequency	O
3.85	O
kHz	O
;	O
140	O
Hz	O
constant	O
;	O
pulse	O
duration	O
130	O
micros	O
;	O
30	O
minutes	O
'	O
duration	O
.	O


Subjects	O
managed	O
by	O
IFT	O
spinal	O
nerve	O
and	O
The	O
Back	O
Book	O
displayed	O
both	O
a	O
statistically	O
significant	O
(	O
p	O
=	O
.030	O
)	O
and	O
clinically	O
meaningful	O
reduction	B-OUT
in	I-OUT
functional	I-OUT
disability	I-OUT
(	I-OUT
RMDQ	I-OUT
)	I-OUT
,	O
compared	O
with	O
management	O
via	O
IFT	O
painful	O
area	O
and	O
The	O
Back	O
Book	O
combined	O
or	O
The	O
Back	O
Book	O
alone	O
.	O


Men	B-P
and	I-P
women	I-P
,	I-P
22-36	I-P
years	I-P
old	I-P
,	O
performed	O
a	O
synchronization-continuation	B-I
task	I-I
with	I-I
intertap	I-I
intervals	I-I
(	I-I
ITI	I-I
)	I-I
from	O
0.4	O
s	O
to	O
2.2	O
s.	O
ISIP	O
variability	O
was	O
partitioned	O
into	O
components	O
attributable	O
to	O
drift	O
and	O
1st-order	O
serial	O
correlation	O
,	O
and	O
the	O
results	O
indicate	O
that	O
(	O
a	O
)	O
drift	O
contributes	O
substantially	O
to	O
the	O
dispersion	O
for	O
longer	O
ITIs	O
,	O
(	O
b	O
)	O
drift	O
and	O
1st-order	O
correlation	O
are	O
different	O
functions	O
of	O
the	O
ITI	O
,	O
and	O
(	O
c	O
)	O
drift	O
exhibits	O
break	O
close	O
to	O
1.0	O
s	O
and	O
1.4	O
s	O
ITI	O
.	O


A	O
randomized	O
,	O
controlled	O
study	O
on	O
the	O
influence	O
of	O
acetaminophen	B-I
,	I-I
diclofenac	I-I
,	I-I
or	I-I
naproxen	I-I
on	I-I
aspirin-induced	I-I
inhibition	O
of	O
platelet	B-OUT
aggregation	I-OUT
.	I-OUT


Nonsteroidal	B-I
anti-inflammatory	I-I
drugs	I-I
(	I-I
NSAID	I-I
)	I-I
may	O
interfere	O
with	O
aspirin	B-I
(	I-I
acetylsalicylic	I-I
acid	I-I
)	I-I
and	O
increase	O
the	O
risk	O
for	O
cardiovascular	B-OUT
events	I-OUT
.	I-OUT


Acetaminophen	B-I
had	O
no	O
effect	O
compared	O
with	O
placebo	B-I
.	I-I


We	O
conclude	O
that	O
a	O
co-administration	O
of	O
NSAID	B-I
and	O
aspirin	B-I
may	O
interfere	O
with	O
platelet	B-OUT
inhibition	I-OUT
at	O
the	O
beginning	O
of	O
a	O
treatment	O
with	O
an	O
increase	O
of	O
naproxen	B-I
and	O
a	O
decrease	O
of	O
diclofenac	B-I
.	I-I


Piperacillin/tazobactam	B-I
plus	I-I
tobramycin	I-I
versus	I-I
ceftazidime	I-I
plus	I-I
tobramycin	I-I
as	O
empiric	O
therapy	O
for	O
fever	B-OUT
in	O
severely	B-P
neutropenic	I-P
patients	I-P
.	I-P


The	O
objective	O
of	O
this	O
trial	O
was	O
to	O
evaluate	O
the	O
potential	O
advantages	O
of	O
the	O
combination	O
of	O
piperacillin	B-I
and	I-I
tazobactam	I-I
in	O
the	O
control	O
of	O
fever	B-OUT
in	I-P
neutropenic	I-P
patients	I-P
.	I-P


In	O
this	O
single-center	O
study	O
,	O
patients	B-P
who	I-P
experienced	I-P
a	I-P
total	I-P
of	I-P
247	I-P
febrile	I-P
episodes	I-P
were	O
prospectively	O
randomized	O
to	O
receive	O
either	O
our	O
standard	O
regimen	O
,	O
ceftazidime	B-I
3	O
g/day	O
(	O
1	O
g	O
t.i.d	O
.	O


)	O
,	O
or	O
piperacillin	B-I
12	O
g/day	O
plus	O
tazobactam	B-I
1.5	O
g/day	O
(	O
4	O
g+0.5	O
g	O
t.i.d	O
.	O


All	B-P
247	I-P
episodes	I-P
were	I-P
evaluable	I-P
by	O
"	O
intent-to-treat	O
"	O
analysis	O
.	O


This	O
trial	O
confirmed	O
the	O
efficacy	B-OUT
of	O
the	O
piperacillin/tazobactam	B-I
combination	O
for	O
empirical	O
treatment	O
of	O
febrile	B-P
neutropenic	I-P
patients	I-P
.	I-P


Qualitative	O
studies	O
suggest	O
that	O
participation	O
in	O
visual	O
arts	O
creative	O
engagement	O
interventions	O
(	O
CEIs	O
)	O
during	O
rehabilitation	O
after	O
stroke	O
may	O
improve	O
mood	B-OUT
,	I-OUT
self-esteem	I-OUT
,	I-OUT
hope	I-OUT
and	O
some	O
aspects	O
of	O
physical	O
recovery	O
.	O


Artists	B-I
will	I-I
follow	I-I
an	I-I
intervention	I-I
protocol	I-I
with	I-I
specific	I-I
components	I-I
that	I-I
enable	I-I
participants	I-I
to	I-I
set	I-I
,	I-I
achieve	I-I
and	I-I
review	I-I
artistic	I-I
goals	I-I
.	I-I


Participants	B-I
will	I-I
receive	I-I
up	I-I
to	I-I
eight	I-I
intervention	I-I
sessions	I-I
,	I-I
four	I-I
within	I-I
a	I-I
group	I-I
and	I-I
four	I-I
one-to-one	I-I
with	I-I
the	I-I
artist	I-I
.	I-I


Stroke-related	B-OUT
health	I-OUT
status	I-OUT
is	O
the	O
primary	O
outcome	O
;	O
mood	B-OUT
,	I-OUT
self-esteem	I-OUT
,	I-OUT
self-efficacy	I-OUT
,	I-OUT
perceived	I-OUT
recovery	I-OUT
control	I-OUT
and	I-OUT
hope	I-OUT
are	I-OUT
secondary	I-OUT
outcomes	O
.	O


Semi-structured	O
interviews	O
will	O
be	O
conducted	O
with	O
purposively	O
selected	O
patients	O
,	O
artists	O
and	O
healthcare	O
staff	O
to	O
elicit	B-OUT
views	I-OUT
and	I-OUT
experiences	I-OUT
of	O
the	O
intervention	O
and	O
feasibility	B-OUT
and	I-OUT
acceptability	I-OUT
of	O
trial	O
processes	O
.	O


Data	O
will	O
indicate	O
,	O
with	O
confidence	O
intervals	O
,	O
the	O
proportion	O
of	O
patients	O
choosing	O
or	O
refusing	O
participation	O
in	O
the	O
CEI	O
and	O
will	O
allow	O
calculation	O
of	O
recruitment	B-OUT
rates	I-OUT
for	O
a	O
future	O
definitive	O
trial	O
.	O


Ambulation	B-I
in	O
labour	O
.	O


The	O
duration	B-OUT
of	I-OUT
labour	I-OUT
was	O
significantly	O
shorter	O
,	O
the	O
need	B-OUT
for	I-OUT
analgesia	I-OUT
significantly	O
less	O
,	O
and	O
the	O
incidence	B-OUT
of	I-OUT
fetal	I-OUT
heart	I-OUT
abnormalities	I-OUT
significantly	O
smaller	O
in	O
the	O
ambulant	O
group	O
than	O
in	O
the	O
recumbent	O
group	O
.	O


Apgar	B-OUT
scores	I-OUT
at	O
one	O
and	O
five	O
minutes	O
were	O
also	O
significantly	O
greater	O
in	O
the	O
ambulant	O
group	O
.	O


More	O
patients	O
in	O
the	O
recumbent	O
group	O
required	O
augmentations	B-OUT
with	I-OUT
oxytocic	I-OUT
drugs	I-OUT
.	I-OUT


Ambulation	B-I
in	O
labour	O
should	O
be	O
encouraged	O
:	O
it	O
may	O
bring	O
human	O
benefits	O
while	O
allowing	O
the	O
advantages	O
of	O
hospital	O
supervision	O
.	O


The	O
amount	O
of	O
PGE-M	O
excreted	O
decreased	O
significantly	O
after	O
administration	O
of	O
indomethacin	B-I
or	O
acetyl	B-I
salicylic	I-I
acid	I-I
in	O
therapeutic	O
doses	O
.	O


The	O
concomitant	O
reduction	O
of	O
the	O
urinary	O
excretion	O
of	O
PGE-M	O
(	O
68	O
to	O
85	O
%	O
decrease	O
)	O
and	O
prostaglandin	O
E	O
(	O
73	O
to	O
100	O
%	O
decrease	O
)	O
after	O
indomethacin	B-I
treatment	O
in	O
each	O
case	O
(	O
n=8	O
)	O
is	O
evidence	O
that	O
a	O
diminished	O
urinary	O
PGE-M	O
output	O
reflects	O
a	O
decrease	O
in	O
prostaglandin	O
E	O
biosynthesis	O
.	O


Phase	O
III	O
trial	O
of	O
satraplatin	B-I
,	O
an	O
oral	O
platinum	B-I
plus	I-I
prednisone	I-I
vs.	I-I
prednisone	I-I
alone	I-I
in	O
patients	B-P
with	I-P
hormone-refractory	I-P
prostate	I-P
cancer	I-P
.	I-P


A	O
randomized	O
multicenter	O
phase	O
III	O
trial	O
with	O
a	O
target	O
sample	O
size	O
of	O
380	B-P
patients	I-P
was	I-P
initiated	I-P
in	I-P
men	I-P
with	I-P
HRPC	I-P
.	I-P


Median	B-OUT
overall	I-OUT
survival	I-OUT
was	O
14.9	O
months	O
(	O
95	O
%	O
CI	O
:	O
13.7-28.4	O
)	O
on	O
the	O
satraplatin	B-I
plus	O
prednisone	B-I
arm	O
and	O
11.9	O
months	O
(	O
95	O
%	O
CI	O
:	O
8.4-23.1	O
)	O
on	O
prednisone	B-I
alone	O
(	O
hazard	O
ratio	O
,	O
HR	O
=	O
0.84	O
,	O
95	O
%	O
CI	O
:	O
0.46-1.55	O
)	O
.	O


A	O
>	O
50	O
%	O
decrease	O
in	O
prostrate	B-OUT
specific	I-OUT
antigen	I-OUT
(	O
PSA	O
)	O
was	O
seen	O
in	O
9/27	O
(	O
33.3	O
%	O
)	O
in	O
the	O
satraplatin	B-I
plus	I-I
prednisone	I-I
arm	O
vs.	O
2/23	O
(	O
8.7	O
%	O
)	O
on	O
the	O
prednisone	B-I
alone	O
arm	O
.	O


It	O
is	O
unknown	O
whether	O
ST	B-I
,	O
with	O
or	O
without	O
concurrent	O
endurance	O
training	O
,	O
would	O
have	O
a	O
similar	O
effect	O
in	O
older	B-P
adults	I-P
with	I-P
reduced	I-P
baseline	I-P
arterial	I-OUT
compliance	I-OUT
.	I-OUT


DESIGN	O
Randomized	O
,	O
controlled	O
intervention	O
study	O
in	O
which	O
37	B-P
healthy	I-P
,	I-P
sedentary	I-P
men	I-P
and	I-P
women	I-P
(	I-P
52+/-2	I-P
years	I-P
)	I-P
performed	I-P
13	I-P
weeks	I-P
of	I-P
ST	I-P
(	I-P
n=13	I-P
)	I-P
,	I-P
ST+aerobic	I-I
exercise	I-I
(	I-P
n=12	I-P
)	I-P
or	I-I
stretching	I-I
exercises	I-I
as	I-I
a	I-I
control	I-I
group	I-I
(	O
n=12	O
)	O
.	O


RESULTS	O
ST	O
performed	O
alone	O
,	O
or	O
in	O
conjunction	O
with	O
aerobic	B-I
exercise	I-I
,	O
improved	O
maximal	B-OUT
muscle	I-OUT
strength	I-OUT
and	I-OUT
increased	I-OUT
total	I-OUT
lean	I-OUT
body	I-OUT
mass	I-OUT
(	O
both	O
P	O
<	O
0.01	O
)	O
.	O


No	O
significant	O
changes	O
were	O
observed	O
in	O
carotid	B-OUT
artery	I-OUT
compliance	I-OUT
or	I-OUT
carotid-femoral	I-OUT
pulse	I-OUT
wave	I-OUT
velocity	I-OUT
following	I-OUT
ST	I-OUT
or	I-OUT
ST+aerobic	I-OUT
exercise	I-OUT
.	I-OUT


Observations	B-OUT
and	I-OUT
tests	I-OUT
were	O
done	O
before	O
and	O
after	O
a	O
period	O
of	O
1	O
year	O
.	O


This	O
is	O
the	O
first	O
phase	O
III	O
randomised	O
trial	O
to	O
evaluate	O
maintenance	O
immunotherapy	O
in	O
metastatic	B-P
renal	I-P
cell	I-P
cancer	I-P
(	O
mRCC	O
)	O
.	O


Patients	B-P
were	O
randomised	O
to	O
receive	O
treatment	O
with	O
a	O
4-week	O
cycle	O
of	O
subcutaneous	B-I
low	I-I
doses	I-I
IL-2	I-I
+	I-I
IFN	I-I
in	O
months	O
1	O
,	O
3	O
and	O
5	O
,	O
and	O
then	O
every	O
3	O
months	O
until	O
the	O
first	O
documented	O
disease	O
progression	O
(	O
arm	O
A	O
,	O
suspension	O
)	O
,	O
or	O
the	O
same	O
regimen	O
,	O
with	O
chronic	O
maintenance	O
of	O
immunotherapy	O
,	O
regardless	O
of	O
tumour	O
response	O
,	O
until	O
death	O
or	O
intolerable	O
toxicity	O
(	O
arm	O
B	O
,	O
maintenance	O
)	O
.	O


The	O
primary	O
endpoint	O
was	O
overall	B-OUT
survival	I-OUT
(	I-OUT
OS	I-OUT
)	I-OUT
;	I-OUT
secondary	O
endpoints	O
were	O
time	B-OUT
from	I-OUT
first	I-OUT
progression	I-OUT
to	I-OUT
death	I-OUT
(	I-OUT
TFPTD	I-OUT
)	I-OUT
and	I-OUT
tolerability	I-OUT
.	I-OUT


After	O
a	O
median	O
follow-up	O
of	O
53.9	O
months	O
,	O
response	B-OUT
rate	I-OUT
,	I-OUT
median	I-OUT
OS	I-OUT
and	I-OUT
median	I-OUT
TFPTD	I-OUT
were	O
14.7	O
%	O
(	O
6.3	O
%	O
CR	O
)	O
versus	O
11.3	O
%	O
(	O
5.5	O
%	O
CR	O
)	O
,	O
14	O
versus	O
14	O
months	O
,	O
6	O
versus	O
5	O
months	O
,	O
in	O
arms	O
A	O
and	O
B	O
,	O
respectively	O
with	O
no	O
significant	O
differences	O
between	O
the	O
groups	O
.	O


Cox	O
regression	O
analysis	O
showed	O
that	O
the	O
use	O
of	O
chemotherapy	B-I
after	O
first	O
progression	O
(	O
HR	O
0.54	O
;	O
95	O
%	O
CI	O
0.35-0.86	O
;	O
p	O
=	O
0.008	O
)	O
,	O
PS	O
=	O
0	O
(	O
HR	O
0.53	O
;	O
95	O
%	O
CI	O
0.35-0.81	O
;	O
p	O
=	O
0.001	O
)	O
and	O
female	O
gender	O
(	O
HR	O
0.63	O
;	O
95	O
%	O
CI	O
0.41-0.98	O
;	O
p	O
=	O
0.038	O
)	O
were	O
significantly	O
associated	O
with	O
a	O
longer	O
TFPTD	B-OUT
;	I-OUT
treatment	O
arm	O
was	O
not	O
significant	O
(	O
HR	O
0.88	O
;	O
95	O
%	O
CI	O
0.60-1.31	O
;	O
p	O
=	O
0.54	O
)	O
.	O


Multi-institutional	O
phase	O
2	O
clinical	O
and	O
pharmacogenomic	O
trial	O
of	O
tipifarnib	B-I
plus	I-I
etoposide	I-I
for	O
elderly	B-P
adults	I-P
with	I-P
newly	I-P
diagnosed	I-P
acute	I-P
myelogenous	I-P
leukemia	I-P
.	I-P


Tipifarnib	O
(	O
T	O
)	O
exhibits	O
modest	O
activity	O
in	O
elderly	B-P
adults	I-P
with	I-P
newly	I-P
diagnosed	I-P
acute	I-P
myelogenous	I-P
leukemia	I-P
(	I-P
AML	I-P
)	I-P
.	I-P


Arm	O
A	O
(	O
T	O
600	O
mg	O
twice	O
a	O
day	O
×	O
14	O
days	O
,	O
E	O
100	O
mg	O
days	O
1-3	O
and	O
8-10	O
)	O
and	O
arm	O
B	O
(	O
T	O
400	O
mg	O
twice	O
a	O
day	O
×	O
14	O
days	O
,	O
E	O
200	O
mg	O
days	O
1-3	O
and	O
8-10	O
)	O
yielded	O
similar	O
CR	O
,	O
but	O
arm	O
B	O
had	O
greater	O
toxicity	B-OUT
.	I-OUT


A	O
2-gene	O
signature	O
of	O
high	O
RASGRP1	O
and	O
low	O
aprataxin	O
(	O
APTX	O
)	O
expression	O
previously	O
predicted	O
for	O
T	O
response	B-OUT
.	O


The	O
treatment	O
of	O
gastrointestinal	B-OUT
cancer	I-OUT
was	O
studied	O
in	O
20	O
phase	O
I	O
,	O
II	O
,	O
and	O
III	O
clinical	O
trials	O
from	B-P
1979	I-P
to	I-P
1983	I-P
at	I-P
30	I-P
member	I-P
institutions	I-P
of	I-P
the	I-P
Southeastern	I-P
Cancer	I-P
Study	I-P
Group	I-P
(	I-P
SECSG	I-P
)	I-P
.	I-P


These	O
studies	O
used	O
both	O
new	B-I
and	I-I
commercially	I-I
available	I-I
drugs	I-I
,	O
as	O
well	O
as	O
surgery	B-I
and/or	I-I
radiation	I-I
therapy	I-I
in	O
1,087	B-P
patients	I-P
.	I-P


No	O
significant	O
benefit	O
was	O
seen	O
from	O
18	B-I
agents	I-I
,	O
and	O
one	O
agent	O
is	O
still	O
under	O
evaluation	O
.	O


METHODS	O
AND	O
RESULTS	O
A	O
total	O
of	O
979	B-P
ST-segment-elevation	I-P
myocardial	I-P
infarction	I-P
patients	I-P
enrolled	I-P
in	I-P
the	I-P
Harmonizing	I-P
Outcomes	I-P
with	I-P
Revascularization	I-P
and	I-P
Stents	I-P
in	I-P
Acute	I-P
Myocardial	I-P
Infarction	I-P
(	I-P
HORIZONS-AMI	I-P
)	I-P
trial	I-P
had	O
BNP	B-OUT
levels	I-OUT
measured	O
in	O
the	O
emergency	O
room	O
prior	O
to	O
primary	O
percutaneous	B-I
coronary	I-I
intervention	I-I
as	O
part	O
of	O
the	O
study	O
protocol	O
.	O


CI-AKI	B-OUT
was	O
defined	O
as	O
a	O
relative	O
increase	O
in	O
serum	O
creatinine	O
of	O
≥25	O
%	O
,	O
or	O
an	O
absolute	O
increase	O
of	O
≥0.5	O
mg/dL	O
,	O
occurring	O
within	O
48	O
hours	O
after	O
contrast	O
administration	B-OUT
.	I-OUT


Logistic	B-OUT
regression	I-OUT
analysis	I-OUT
was	O
used	O
to	O
estimate	O
the	O
association	O
of	O
admission	O
BNP	O
with	O
development	O
of	O
CI-AKI	B-OUT
.	I-OUT


After	O
multivariable	O
adjustment	O
for	O
clinical	O
,	O
laboratory	O
,	O
and	O
angiographic	O
variables	B-OUT
,	O
BNP	O
remained	O
a	O
significant	O
independent	O
predictor	O
of	O
CI-AKI	O
(	O
1.29	O
[	O
1.10	O
,	O
1.51	O
]	O
;	O
P	O
<	O
0.001	O
)	O
.	O


CONCLUSIONS	O
Measurement	B-OUT
of	I-OUT
serum	I-OUT
BNP	O
at	O
hospital	O
admission	O
may	O
help	O
identify	B-P
patients	I-P
who	I-P
are	I-P
at	I-P
risk	I-P
for	I-P
developing	I-P
CI-AKI	I-P
after	I-I
primary	I-I
percutaneous	I-I
coronary	I-I
intervention	I-I
in	I-P
ST-segment-elevation	I-P
myocardial	I-P
infarction	I-P
.	O


The	O
use	O
of	O
vascularized	B-I
bone	I-I
grafts	I-I
to	O
reconstruct	O
extremity	O
and	O
mandibular	O
defects	O
is	O
now	O
commonplace	O
in	O
reconstructive	O
surgery	O
.	O


Five	B-P
pairs	I-P
of	I-P
human	I-P
radii	I-P
were	I-P
used	I-P
for	I-P
the	I-P
control	I-P
in	I-P
the	I-P
pilot	I-P
study	I-P
.	I-P


PURPOSE	O
Cancer	B-OUT
related	I-OUT
fatigue	I-OUT
(	I-OUT
CRF	I-OUT
)	I-OUT
is	O
a	O
common	O
problem	O
for	O
cancer	B-P
patients	I-P
across	I-P
diagnoses	I-P
during	I-P
chemotherapy	I-I
and	O
is	O
associated	O
with	O
physical	O
inactivity	O
,	O
lower	O
functional	O
level	O
and	O
lack	O
of	O
energy	O
.	O


The	O
objective	O
of	O
this	O
study	O
is	O
to	O
evaluate	O
whether	O
a	O
six-week	O
supervised	B-I
multimodal	I-I
exercise	I-I
intervention	I-I
,	I-I
adjunct	I-I
to	I-I
chemotherapy	I-I
and	I-I
standard	I-I
care	I-I
,	O
can	O
reduce	O
the	O
patient	O
's	O
CRF	B-OUT
level	I-OUT
.	I-OUT


213	B-P
cancer	I-P
patients	I-P
with	I-P
different	I-P
diagnoses	I-P
were	O
randomised	O
into	B-P
an	O
intervention	B-I
group	I-I
or	O
wait-list	B-I
control	I-I
group	I-I
.	I-I


The	O
primary	O
outcome	O
,	O
Fatigue	B-OUT
score	I-OUT
(	I-OUT
CRF	I-OUT
)	I-OUT
,	O
was	O
evaluated	O
by	O
the	O
Functional	B-OUT
Assessment	I-OUT
of	I-OUT
Cancer	I-OUT
Therapy-Anaemia	I-OUT
Questionnaire	I-OUT
(	I-OUT
FACT-An-	I-OUT
)	I-OUT
(	I-OUT
FACT-G	I-OUT
score	I-OUT
&	I-OUT
FACT-An	I-OUT
Anemia	I-OUT
subscale	I-OUT
)	I-OUT
.	I-OUT


RESULTS	O
CRF	B-OUT
was	O
significantly	O
reduced	O
in	O
the	O
intervention	O
group	O
,	O
corresponding	O
to	O
a	O
Fatigue	B-OUT
score	I-OUT
reduction	I-OUT
of	O
3.04	O
(	O
effect	O
size	O
of	O
0.44	O
,	O
95	O
%	O
CI	O
0.17-0.72	O
)	O
(	O
P	O
=	O
.002	O
)	O
,	O
the	O
FACT-An	B-OUT
score	I-OUT
by	O
5.40	O
(	O
P	O
=	O
.015	O
)	O
,	O
the	O
FACT-An	B-OUT
Toi	I-OUT
score	O
by	O
5.22	O
(	O
P	O
=	O
.009	O
)	O
and	O
the	O
Anaemia-ANS	B-OUT
by	O
3.76	O
(	O
P	O
=	O
.002	O
)	O
.	O


CONCLUSION	O
In	O
summary	O
,	O
this	O
six-week	O
supervised	B-I
multimodal	I-I
exercise	I-I
intervention	I-I
can	O
lead	O
to	O
significant	O
reduction	O
in	O
self-reported	B-OUT
CRF	I-OUT
in	I-P
cancer	I-P
patients	I-P
undergoing	I-P
chemotherapy	I-P
.	I-P


Histologic	B-OUT
conversion	I-OUT
in	O
the	O
non-Hodgkin	B-P
's	I-P
lymphomas	I-P
.	I-P


Among	O
patients	O
who	O
achieved	B-OUT
a	I-OUT
CR	I-OUT
,	O
31	O
%	O
later	O
relapsed	B-OUT
.	I-OUT


The	O
most	B-OUT
common	I-OUT
type	O
of	O
histologic	B-OUT
conversion	I-OUT
was	O
from	O
NLPD	O
to	O
diffuse	O
histiocytic	B-OUT
lymphoma	I-OUT
.	I-OUT


However	O
,	O
those	O
patients	O
who	O
achieved	B-OUT
a	I-OUT
CR	I-OUT
after	O
conversion	B-OUT
had	O
a	O
more	O
favorable	B-OUT
outcome	I-OUT
(	I-OUT
actuarial	I-OUT
survival	I-OUT
75	O
%	O
at	O
5	O
yr	O
)	O
.	O


OBJECTIVE	O
To	O
compare	B-OUT
elastic	I-I
stable	I-I
intramedullary	I-I
nailing	I-I
(	I-I
ESIN	I-I
)	I-I
with	O
nonoperative	B-I
treatment	I-I
of	O
fully	B-P
displaced	I-P
midshaft	I-P
clavicular	I-P
fractures	I-P
in	I-P
adults	I-P
.	I-P


PATIENTS	O
AND	O
METHODS	O
Sixty	B-P
patients	I-P
between	I-P
18	I-P
and	I-P
65	I-P
years	I-P
of	I-P
age	I-P
participated	I-P
and	I-P
completed	I-P
the	I-P
study	I-P
.	I-P


INTERVENTION	O
Thirty	O
patients	O
were	O
treated	O
with	O
a	O
simple	B-I
shoulder	I-I
sling	I-I
and	O
30	O
patients	O
with	O
ESIN	B-I
within	O
3	O
days	O
after	O
trauma	O
.	O


MAIN	O
OUTCOME	O
MEASUREMENT	O
Complications	B-OUT
after	O
operative	O
and	O
nonoperative	O
treatments	O
,	O
Disabilities	B-OUT
of	I-OUT
the	I-OUT
Arm	I-OUT
,	I-OUT
Shoulder	I-OUT
and	I-OUT
Hand	I-OUT
(	I-OUT
DASH	I-OUT
)	I-OUT
score	I-OUT
and	O
Constant	B-OUT
Shoulder	I-OUT
Score	I-OUT
for	O
outcome	B-OUT
measurement	I-OUT
,	O
and	O
clavicular	B-OUT
shortening	I-OUT
.	I-OUT


RESULTS	O
Fracture	B-OUT
union	I-OUT
was	O
achieved	O
in	O
all	O
patients	O
in	O
the	O
operative	O
group	O
,	O
whereas	O
nonunion	B-OUT
was	O
observed	O
in	O
3	O
of	O
30	O
patients	O
of	O
the	O
nonoperative	O
group	O
.	O


Two	O
symptomatic	B-OUT
malunions	I-OUT
required	O
corrective	O
osteotomy	O
in	O
the	O
nonoperative	O
group	O
.	O


Constant	B-OUT
scores	I-OUT
were	O
significantly	O
higher	O
after	O
6	O
months	O
and	O
2	O
years	O
after	O
intramedullary	O
stabilization	O
.	O


Patients	O
in	O
the	O
operative	O
group	O
showed	O
a	O
significant	O
improvement	O
of	O
posttraumatic	B-OUT
clavicular	I-OUT
shortening	I-OUT
;	I-OUT
they	O
were	O
also	O
more	O
satisfied	B-OUT
with	O
cosmetic	O
appearance	O
and	O
overall	B-OUT
outcome	I-OUT
.	I-OUT


Clavicular	B-OUT
shortening	I-OUT
was	O
significantly	O
lower	O
,	O
and	O
overall	B-OUT
satisfaction	I-OUT
was	O
higher	O
in	O
the	O
operative	O
group	O
.	O


A	O
single	B-I
nasal	I-I
allergen	I-I
challenge	I-I
increases	O
induced	O
sputum	B-OUT
inflammatory	I-OUT
markers	I-OUT
in	O
non-asthmatic	B-P
subjects	I-P
with	I-P
seasonal	I-P
allergic	I-P
rhinitis	I-P
:	I-P
correlation	O
with	O
plasma	O
interleukin-5	O
.	O


OBJECTIVE	O
To	O
assess	O
the	O
impact	O
of	O
nasal	O
allergy	O
on	O
sputum	B-OUT
inflammatory	I-OUT
markers	I-OUT
.	I-OUT


After	B-I
a	I-I
washout	I-I
period	I-I
of	I-I
at	I-I
least	I-I
4	I-I
weeks	I-I
,	I-I
the	I-I
procedure	I-I
was	I-I
repeated	I-I
with	I-I
placebo	I-I
challenge	I-I
(	I-I
diluent	I-I
)	I-I
.	I-I


The	O
absolute	O
number	O
of	O
blood	B-OUT
and	I-OUT
sputum	I-OUT
eosinophils	I-OUT
did	O
not	O
change	O
significantly	O
after	O
allergen	O
or	O
placebo	O
challenge	O
(	O
P	O
>	O
0.07	O
,	O
both	O
comparisons	O
)	O
.	O


Plasma	B-OUT
levels	I-OUT
of	I-OUT
IL-5	I-OUT
increased	O
after	O
allergen	O
challenge	O
(	O
8.7	O
+/-	O
2.9	O
to	O
14.5	O
+/-	O
3.9	O
pg/mL	O
,	O
P	O
=	O
0.001	O
)	O
,	O
and	O
the	O
increase	O
in	O
plasma	O
IL-5	O
was	O
positively	O
correlated	O
with	O
the	O
rise	O
in	O
sputum	B-OUT
ECP	I-OUT
in	O
a	O
subgroup	O
of	O
'responders	O
'	O
(	O
n	O
=	O
12	O
,	O
r	O
=	O
0.71	O
,	O
P	O
=	O
0.01	O
)	O
.	O


These	O
findings	O
may	O
provide	O
additional	O
explanatory	O
data	O
for	O
the	O
high	O
susceptibility	O
of	O
SAR	B-P
patients	I-P
to	O
incident	O
asthma	O
.	O


Once-daily	O
MMX	B-I
(	I-I
®	I-I
)	I-I
mesalamine	I-I
for	O
endoscopic	O
maintenance	O
of	O
remission	O
of	B-P
ulcerative	I-P
colitis	I-P
.	O


RESULTS	O
Overall	B-P
,	I-P
826	I-P
patients	I-P
were	I-P
randomized	I-P
and	I-P
dosed	I-P
.	O


At	O
month	O
6	O
,	O
83.7	O
and	O
77.8	O
%	O
of	O
patients	O
receiving	O
MMX	O
mesalamine	O
in	O
the	O
PP	O
and	O
intent-to-treat	O
(	O
ITT	O
)	O
populations	O
,	O
respectively	O
,	O
had	O
maintained	B-OUT
endoscopic	I-OUT
remission	I-OUT
compared	O
with	O
81.5	O
%	O
(	O
PP	O
)	O
and	O
76.9	O
%	O
(	O
ITT	O
)	O
of	O
patients	O
receiving	O
delayed-release	O
mesalamine	O
(	O
95	O
%	O
confidence	O
interval	O
for	O
difference	O
:	O
-3.9	O
%	O
,	O
8.1	O
%	O
(	O
PP	O
)	O
;	O
-5.0	O
%	O
,	O
6.9	O
%	O
(	B-OUT
ITT	I-OUT
)	I-OUT
)	I-OUT
.	I-OUT


Comparison	O
of	O
four	O
continuously	O
administered	O
progestogen	B-I
plus	I-I
oestradiol	I-I
combinations	O
for	O
climacteric	B-OUT
complaints	I-OUT
.	I-OUT


Sixty	B-P
women	I-P
with	I-P
climacteric	I-P
complaints	I-P
who	I-P
had	I-P
not	I-P
menstruated	I-P
for	I-P
at	I-P
least	I-P
1	I-P
year	I-P
were	O
randomly	O
allocated	O
to	O
receive	O
one	O
of	O
four	O
hormonal	O
replacement	O
regimens	O
.	O


The	O
clinical	B-OUT
efficacy	I-OUT
was	O
the	O
same	O
although	O
the	O
alleviation	O
of	O
vasomotor	B-OUT
symptoms	I-OUT
was	O
somewhat	O
slower	O
in	O
those	O
women	O
receiving	O
preparation	O
A	O
.	O


Irregular	B-OUT
uterine	I-OUT
bleeding	I-OUT
was	O
almost	O
entirely	O
confined	O
to	O
the	O
earlier	O
phase	O
of	O
the	O
study	O
and	O
was	O
substantially	O
less	O
with	O
the	O
formulation	O
containing	O
1	O
mg	O
norethisterone	B-I
acetate	I-I
.	I-I


It	O
is	O
concluded	O
that	O
a	O
continuous	O
oestradiol-progestogen	B-I
combination	I-I
can	O
be	O
used	O
for	O
long-term	O
treatment	O
of	O
climacteric	B-OUT
complaints	I-OUT
in	I-P
postmenopausal	I-P
women	I-P
and	O
that	O
after	O
4	O
months	O
the	O
clinical	B-OUT
efficacy	I-OUT
is	O
the	O
same	O
irrespective	O
of	O
the	O
type	O
and	O
dose	O
of	O
progestogen	B-I
administered	O
.	O


Self-reported	B-OUT
smoking	I-OUT
and	I-OUT
drinking	I-OUT
and	I-P
the	I-P
number	I-P
of	I-P
substance	I-P
using	I-P
friends	I-P
were	I-P
assessed	I-P
5	I-P
times	I-P
over	I-P
3	I-P
years	I-P
.	I-P


The	O
relationship	B-I
between	I-I
peer	I-OUT
and	I-OUT
adolescent	I-OUT
substance	I-OUT
use	I-OUT
were	I-I
assessed	I-I
in	I-I
parallel	I-I
processes	I-I
as	I-I
part	I-I
of	I-I
an	I-I
autoregressive	I-I
latent	I-I
trajectory	I-I
model	I-I
.	I-I


Bivariate	O
,	O
lagged	O
autoregressive	O
analyses	O
of	O
the	O
successive	O
relationships	O
from	O
one	O
assessment	O
to	O
the	O
next	O
showed	O
consistent	O
,	O
significant	O
associations	O
from	O
peer	B-OUT
use	I-OUT
to	I-OUT
adolescent	I-OUT
substance	I-OUT
use	I-OUT
.	I-OUT


The	O
association	O
from	O
adolescent	B-OUT
to	I-OUT
peer	I-OUT
use	I-OUT
was	O
significant	O
only	O
from	O
7th	O
to	O
8th	O
grade	O
.	O


Peptide	B-OUT
T	I-OUT
:	I-OUT
negative	I-OUT
trial	I-OUT
result	I-OUT
.	I-OUT


While	O
there	O
was	O
no	O
statistically	O
significant	O
in	O
the	O
number	O
of	O
lymph	B-OUT
node	I-OUT
dissection	I-OUT
,	I-OUT
operative	I-OUT
time	I-OUT
and	I-OUT
postoperative	I-OUT
chest	I-OUT
tube	I-OUT
drainage	I-OUT
time	I-OUT
.	I-OUT


The	O
effect	O
of	O
surgical	O
trauma	O
and	O
insulin	B-I
on	O
whole-body	B-OUT
protein	I-OUT
turnover	I-OUT
in	O
parenterally-fed	B-P
undernourished	I-P
patients	I-P
.	I-P


Pre-operatively	O
,	O
and	O
2	O
h	O
after	O
commencing	O
their	O
post-operative	O
feeds	O
,	O
rates	B-OUT
of	I-OUT
whole-body	I-OUT
protein	I-OUT
synthesis	I-OUT
and	I-OUT
breakdown	I-OUT
were	O
measured	O
over	O
a	O
9-h	O
period	O
following	O
intravenous	O
injection	O
of	O
a	O
single	O
tracer	O
dose	O
of	O
15N-glycine	B-I
by	O
the	O
ammonia	O
and	O
urea	O
end-product	O
methods	O
.	O


Blood	B-OUT
glucose	I-OUT
and	I-OUT
plasma	I-OUT
insulin	I-OUT
and	I-OUT
glucagon	I-OUT
concentrations	I-OUT
rose	O
post-operatively	O
whether	O
or	O
not	O
insulin	B-I
was	O
given	O
,	O
but	O
the	O
increment	O
in	O
insulin	B-OUT
concentration	I-OUT
was	O
significantly	O
greater	O
when	O
insulin	B-I
was	O
given	O
.	O


Apparent	B-OUT
nitrogen	I-OUT
balance	I-OUT
was	O
positive	O
pre-operatively	O
and	O
became	O
less	O
so	O
post-operatively	O
whether	O
insulin	B-I
was	O
given	O
or	O
not	O
.	O


Similarly	O
,	O
post-operative	O
increments	O
in	O
urinary	B-OUT
excretion	I-OUT
of	I-OUT
ammonia	I-OUT
,	I-OUT
creatinine	I-OUT
and	I-OUT
3-methylhistidine	I-OUT
were	O
not	O
altered	O
by	O
addition	O
of	O
insulin	B-I
.	I-I


The	O
urea	O
end-product	O
method	O
suggested	O
that	O
there	O
was	O
no	O
change	O
in	O
whole-body	B-OUT
protein	I-OUT
turnover	I-OUT
after	O
surgery	O
,	O
whether	O
or	O
not	O
insulin	B-I
was	O
given	O
.	O


This	O
study	O
does	O
not	O
support	O
the	O
clinical	O
use	O
of	O
insulin	B-OUT
as	O
a	O
means	O
of	O
modifying	O
protein	O
metabolic	O
losses	O
after	O
major	B-P
surgery	I-P
.	I-P


Impact	O
of	O
work	B-I
site	I-I
health	I-I
promotion	I-I
on	O
stages	B-P
of	I-P
dietary	I-P
change	I-P
:	I-P
the	O
Working	O
Well	O
Trial	O
.	O


This	O
report	O
examines	O
associations	O
of	O
stages	O
of	O
change	O
with	O
diet	O
prospectively	O
and	O
addresses	O
whether	O
(	O
1	O
)	O
baseline	O
stage	O
of	O
change	O
predicts	O
participation	O
,	O
(	O
2	O
)	O
forward	O
changes	O
in	O
stage	O
movement	O
were	O
greater	O
in	O
treatment	O
work	O
sites	O
,	O
and	O
(	O
3	O
)	O
change	O
in	O
stage	O
was	O
associated	O
with	O
adoption	O
of	O
healthful	O
diets	O
,	O
using	O
data	O
from	O
a	B-P
cohort	I-P
of	I-P
11,237	I-P
employees	I-P
.	I-P


Findings	O
indicate	O
that	O
persons	B-P
in	I-P
later	I-P
stages	I-P
of	I-P
change	I-P
reported	O
higher	O
participation	O
levels	O
.	O


Net	B-OUT
change	I-OUT
in	O
diet	O
due	O
to	O
the	O
intervention	O
was	O
modest	O
.	O


Drug	O
preference	O
in	O
normal	B-P
volunteers	I-P
:	I-P
effects	O
of	O
age	O
and	O
time	O
of	O
day	O
.	O


Three	B-P
groups	I-P
of	I-P
subjects	I-P
were	I-P
tested	I-P
:	I-P
i	I-P
)	I-P
a	I-P
group	I-P
of	I-P
40-55-year-old	I-P
subjects	I-P
(	I-P
AGE	I-P
group	I-P
;	I-P
N	I-P
=	I-P
11	I-P
)	I-P
who	I-P
were	I-P
tested	I-P
in	I-P
the	I-P
morning	I-P
,	I-P
ii	I-P
)	I-P
a	I-P
group	I-P
of	I-P
21-35-year-old	I-P
subjects	I-P
(	I-P
CTL	I-P
group	I-P
;	I-P
N	I-P
=	I-P
12	I-P
)	I-P
who	I-P
were	I-P
also	I-P
tested	I-P
in	I-P
the	I-P
morning	I-P
,	I-P
and	I-P
iii	I-P
)	I-P
a	I-P
group	I-P
of	I-P
21-35-year-olds	I-P
who	I-P
were	I-P
tested	I-P
in	I-P
the	I-P
late	I-P
afternoon	I-P
(	I-P
AFT	I-P
group	I-P
;	I-P
N	I-P
=	I-P
13	I-P
)	I-P
.	I-P


Disclosure	O
of	O
HSV-2	O
serological	O
test	O
results	O
in	O
the	O
context	O
of	O
an	O
adolescent	B-P
HIV	I-P
prevention	I-P
trial	I-P
in	I-P
Kenya	I-P
.	I-P


OBJECTIVES	O
Herpes	O
simplex	O
virus	O
type	O
2	O
(	O
HSV-2	O
)	O
biomarkers	O
are	O
often	O
used	O
in	O
adolescent	B-P
sub-Saharan	I-P
HIV	I-P
prevention	I-P
studies	O
,	O
but	O
evaluations	O
of	O
test	O
performance	O
and	O
disclosure	O
outcomes	O
are	O
rare	O
in	O
the	O
published	O
literature	O
.	O


METHODS	O
In	O
2011	O
,	O
837	B-P
Kenyan	I-P
orphan	I-P
youth	I-P
in	I-P
grades	I-P
7	I-P
and	I-P
8	I-P
enrolled	I-P
in	I-P
an	I-P
HIV	I-P
prevention	I-P
clinical	I-P
trial	I-P
with	I-P
HSV-2	I-P
biomarker	I-P
outcomes	I-P
.	I-P


Of	O
these	O
,	O
22	B-P
positive	I-P
and	I-P
all	I-P
indeterminates	I-P
were	I-P
WB	I-P
tested	I-P
;	I-P
20	I-P
and	I-P
5	I-P
,	I-P
respectively	I-P
,	O
were	O
confirmed	O
positive	O
.	O


Self-reported	B-OUT
virginity	I-OUT
was	O
highly	O
inconsistent	O
with	O
WB-confirmed	B-OUT
positives	I-OUT
.	I-OUT


Determinants	O
of	O
total	O
and	O
specific	O
IgE	O
in	O
infants	B-P
with	I-P
atopic	I-P
dermatitis	I-P
.	I-P


In	O
infancy	O
,	O
increased	O
total	B-OUT
IgE	I-OUT
is	O
more	O
affected	O
by	O
factors	O
increasing	O
risk	O
of	O
intercurrent	O
infection	O
and	O
non-specific	O
airway	O
inflammation	O
,	O
such	O
as	O
environmental	O
tobacco	O
smoke	O
exposure	O
(	O
p	O
<	O
0.001	O
)	O
and	O
the	O
use	O
of	O
gas	O
cookers	O
(	O
p	O
=	O
0.02	O
)	O
.	O


Specific	O
allergen	B-OUT
sensitization	I-OUT
as	O
represented	O
by	O
detectable	O
IgE	B-OUT
antibodies	I-OUT
is	O
influenced	O
primarily	O
by	O
allergen	O
exposure	O
.	O


[	B-I
Median	I-I
and	I-I
mediolateral	I-I
episiotomy	I-I
]	I-I
.	I-P


One	O
intervention	O
involved	O
a	O
peer-mediated	B-I
approach	I-I
(	I-I
PEER	I-I
)	I-I
and	O
the	O
other	O
involved	O
a	O
child-assisted	B-I
approach	I-I
(	I-I
CHILD	I-I
)	I-I
.	I-I


Sixty	B-P
children	I-P
participated	I-P
from	I-P
56	I-P
classrooms	I-P
in	I-P
30	I-P
schools	I-P
.	O


CONCLUSIONS	O
These	O
data	O
suggest	O
that	O
significant	O
improvements	O
can	O
be	O
made	B-OUT
in	I-OUT
peer	I-OUT
social	I-OUT
connections	I-OUT
for	O
children	O
with	B-P
autism	I-P
spectrum	I-P
disorders	I-P
in	O
general	O
education	O
classrooms	O
with	O
a	O
brief	O
intervention	O
,	O
and	O
that	O
these	O
gains	O
persist	O
over	O
time	O
.	O


Lower	O
relapse	O
rates	O
after	O
neighbourhood	O
injection	O
of	O
Corynebacterium	B-I
parvum	I-I
in	O
operable	O
cervix	O
carcinoma	O
.	O


All	B-P
patients	I-P
had	I-P
carcinoma	I-P
confined	I-P
to	I-P
the	I-P
cervix	I-P
,	I-P
the	I-P
upper	I-P
part	I-P
of	I-P
the	I-P
vagina	I-P
or	I-P
the	I-P
parametrial	I-P
region	I-P
.	I-P


Only	O
minor	O
side	B-OUT
effects	I-OUT
of	O
CP	O
were	O
encountered	O
.	O


A	O
further	O
15	B-P
patients	I-P
with	I-P
more	I-P
advanced	I-P
malignancies	I-P
were	I-P
added	I-P
to	I-P
our	I-P
studies	I-P
.	I-P


In	O
these	O
,	O
CP	B-I
stimulation	I-I
had	O
no	O
effect	O
on	O
relapse	B-OUT
rates	I-OUT
,	O
but	O
the	O
relapse-free	B-OUT
intervals	I-OUT
were	O
longer	O
after	O
immune	B-I
stimulation	I-I
:	I-I
control	O
3.5	O
months	O
(	O
mean	O
)	O
+/-	O
1.5	O
(	O
s.d	O
.	O


The	O
potential	O
interaction	O
between	O
racemic	B-I
warfarin	I-I
given	O
as	O
a	O
25	B-I
mg	I-I
single	I-I
oral	I-I
dose	I-I
and	I-I
chronically	I-I
administered	I-I
ketorolac	I-I
was	O
studied	O
in	O
12	B-P
young	I-P
healthy	I-P
male	I-P
volunteers	I-P
.	I-P


Ketorolac	B-I
produced	O
no	B-OUT
major	I-OUT
change	I-OUT
in	I-OUT
the	I-OUT
pharmacokinetics	I-OUT
of	I-OUT
(	I-OUT
R	I-OUT
)	I-OUT
-	I-OUT
or	I-OUT
(	I-OUT
S	I-OUT
)	I-OUT
-warfarin	I-OUT
.	I-OUT


Ketorolac	B-I
increased	I-OUT
template	I-OUT
bleeding	I-OUT
time	I-OUT
by	O
a	O
factor	O
of	O
1.35	O
as	O
compared	O
with	O
placebo	O
.	O


Positive	O
impact	O
of	O
crisis	B-I
resource	I-I
management	I-I
training	I-I
on	O
no-flow	O
time	O
and	O
team	O
member	O
verbalisations	O
during	O
simulated	B-I
cardiopulmonary	I-I
resuscitation	I-I
:	I-I
a	O
randomised	O
controlled	O
trial	O
.	O


RESULTS	B-OUT
NFT	I-OUT
rates	I-OUT
were	O
significantly	O
lower	O
in	O
the	O
CRM-training	O
group	O
(	O
31.4±6.1	O
%	O
vs.	O
36.3±6.6	O
%	O
,	O
p=0.014	O
)	O
.	O


OBJECTIVE	O
To	O
investigate	O
the	O
effect	O
of	O
exercise	B-I
training	I-I
and	I-I
dietary	I-I
macronutrient	I-I
composition	I-I
on	O
24	B-OUT
h	I-OUT
substrate	I-OUT
oxidation	I-OUT
in	O
male	B-P
,	I-P
obese	I-P
subjects	I-P
.	I-P


DESIGN	O
A	O
16	O
month	O
exercise	B-I
intervention	I-I
study	O
was	O
executed	O
,	O
including	O
a	O
weight	O
loss	O
period	O
with	O
a	O
very	B-I
low	I-I
energy	I-I
diet	I-I
(	I-I
VLED	I-I
)	I-I
for	O
2	O
months	O
at	O
the	O
start	O
of	O
the	O
study	O
.	O


MEASUREMENTS	O
Substrate	B-OUT
oxidation	I-OUT
was	O
measured	O
during	O
a	O
standardized	O
36	O
h	O
stay	O
in	O
the	O
respiration	O
chamber	O
at	O
the	O
start	O
of	O
the	O
study	O
(	O
0	O
months	O
)	O
,	O
and	O
at	O
4	O
,	O
10	O
and	O
16	O
months	O
.	O


In	O
the	O
respiration	O
chamber	O
subjects	B-P
were	I-P
randomly	I-P
assigned	I-P
to	O
a	O
high-fat	B-I
(	I-I
Hi.F	I-I
)	I-I
diet	I-I
(	I-I
60	I-I
%	I-I
of	I-I
energy	I-I
(	I-I
En	I-I
%	I-I
)	I-I
fat	I-I
)	I-I
or	I-I
a	I-I
reduced-fat	I-I
(	I-I
Red.F	I-I
)	I-I
diet	I-I
(	I-I
30	I-I
En	I-I
%	I-I
fat	I-I
)	I-I
.	I-I


In	O
the	O
well-trained	O
group	O
the	O
24h	B-OUT
CHO	I-OUT
balance	I-OUT
was	O
even	O
more	O
negative	O
for	O
both	O
types	O
of	O
diet	O
(	O
-103	O
to	O
-185	O
g/d	O
for	O
the	O
Red.F	O
and	O
Hi.F	O
diet	O
,	O
respectively	O
)	O
under	O
similar	O
conditions	O
compared	O
with	O
the	O
trained	O
obese	O
group	O
.	O


CONCLUSION	O
The	O
changes	O
in	O
24	B-OUT
h	I-OUT
substrate	I-OUT
utilization	I-OUT
in	O
the	O
obese	O
,	O
as	O
well	O
as	O
in	O
the	O
well-trained	O
group	O
,	O
suggest	O
that	O
endurance	O
training	O
increased	O
the	O
reliance	O
on	O
carbohydrate	B-OUT
oxidation	I-OUT
and	O
therefore	O
did	O
not	O
increase	O
24	B-OUT
fat	I-OUT
oxidation	I-OUT
.	I-OUT


DESIGN	O
Two	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	B-I
trials	O
conducted	O
between	O
June	O
and	O
July	O
1997	O
.	O


SETTING	O
Individual	O
hotel	O
rooms	O
;	O
2	B-P
large	I-P
US	I-P
university	I-P
medical	I-P
schools	I-P
.	I-P


PARTICIPANTS	O
A	B-P
total	I-P
of	I-P
117	I-P
healthy	I-P
adult	I-P
volunteers	I-P
(	I-P
aged	I-P
18-40	I-P
years	I-P
;	I-P
median	I-P
age	I-P
,	I-P
21	I-P
years	I-P
)	I-P
who	I-P
were	I-P
susceptible	I-P
(	I-P
hemagglutination-inhibition	I-P
antibody	I-P
titer	I-P
<	I-P
or	I-P
=1:8	I-P
)	I-P
.	I-P


For	O
the	O
prophylaxis	O
study	O
,	O
oral	B-I
oseltamivir	I-I
(	O
100	O
mg	O
once	O
daily	O
[	O
n	O
=	O
12	O
]	O
,	O
100	O
mg	O
twice	O
daily	O
[	O
n	O
=	O
12	O
]	O
,	O
or	O
matching	B-I
placebo	I-I
[	O
n	O
=	O
13	O
]	O
,	O
starting	O
26	O
hours	O
before	O
virus	O
inoculation	O
)	O
was	O
administered	O
.	O


For	O
the	O
treatment	O
study	O
,	O
the	O
same	O
drug	O
was	O
given	O
(	O
20	O
mg	O
,	O
100	O
mg	O
,	O
or	O
200	O
mg	O
twice	O
daily	O
,	O
200	O
mg	O
once	O
daily	O
,	O
or	O
matching	O
placebo	B-I
[	O
n	O
=	O
16	O
]	O
,	O
in	O
each	O
group	O
starting	O
28	O
hours	O
after	O
inoculation	O
)	O
.	O


MAIN	O
OUTCOME	O
MEASURES	O
Comparing	O
placebo	O
groups	O
with	O
pooled	O
treatment	O
groups	O
,	O
for	O
prophylaxis	O
,	O
outcomes	O
included	O
frequency	B-OUT
of	I-OUT
infection	I-OUT
and	I-OUT
viral	I-OUT
shedding	I-OUT
;	I-OUT
for	O
treatment	O
,	O
viral	O
shedding	O
in	O
titers	O
.	O


Oseltamivir	O
treatment	O
also	O
reduced	O
symptom	B-OUT
scores	I-OUT
(	O
median	O
[	O
IQR	O
]	O
score-hours	O
,	O
225	O
[	O
97-349	O
]	O
vs	O
400	O
[	O
189-645	O
]	O
;	O
P	O
=	O
.05	O
)	O
,	O
and	O
nasal	B-OUT
proinflammatory	I-OUT
cytokine	I-OUT
levels	I-OUT
.	I-OUT


CONCLUSIONS	O
In	O
these	O
trials	O
,	O
prophylaxis	O
and	O
early	O
treatment	O
with	O
oral	O
oseltamivir	O
were	O
both	O
associated	O
with	O
significant	O
antiviral	O
and	O
clinical	O
effects	O
in	O
experimental	B-P
human	I-P
influenza	I-P
.	O


Antazoline	B-I
is	O
a	O
first	O
generation	O
antihistaminic	O
agent	O
with	O
chinidin-like	O
properties	O
.	O


When	O
administered	O
intravenously	O
,	O
antazoline	B-I
exerts	O
a	O
strong	B-OUT
antiarrhythmic	I-OUT
effect	I-OUT
on	O
supraventricular	B-OUT
arrhythmia	I-OUT
,	O
especially	O
on	O
AF	B-OUT
,	O
facilitating	O
rapid	B-OUT
conversion	I-OUT
to	I-OUT
sinus	I-OUT
rhythm	I-OUT
.	I-OUT


METHODS/DESIGN	O
A	O
randomized	O
,	O
double	O
blind	O
,	O
placebo-controlled	B-I
,	O
superiority	O
clinical	O
trial	O
was	O
designed	O
to	O
assess	O
clinical	B-OUT
efficacy	I-OUT
of	O
antazoline	B-I
in	O
rapid	O
conversion	O
of	O
AF	O
to	O
sinus	O
rhythm	O
.	O


Eligible	B-P
patients	I-P
will	I-P
present	I-P
AF	I-P
lasting	I-P
less	I-P
than	I-P
43	I-P
hours	I-P
,	I-P
will	I-P
be	I-P
in	I-P
stable	I-P
cardio-pulmonary	I-P
condition	I-P
and	I-P
will	I-P
have	I-P
no	I-P
prior	I-P
history	I-P
of	I-P
advanced	I-P
heart	I-P
failure	I-P
or	I-P
significant	I-P
valvular	I-P
disease	I-P
.	I-P


Primary	O
end	O
point	O
will	O
be	O
the	O
conversion	B-OUT
of	I-OUT
AF	I-OUT
to	I-OUT
sinus	I-OUT
rhythm	I-OUT
confirmed	I-OUT
in	I-OUT
an	I-OUT
electrocardiogram	I-OUT
(	I-OUT
ECG	I-OUT
)	I-OUT
during	O
the	O
observation	O
period	O
.	O


Special	O
consideration	O
will	O
be	O
given	O
to	O
the	O
observation	O
of	O
any	O
adverse	B-OUT
events	I-OUT
.	I-OUT


Effective	O
strategies	O
included	O
(	O
a	O
)	O
the	B-I
use	I-I
of	I-I
choral	I-I
responding	I-I
;	I-I
(	O
b	O
)	O
the	B-I
use	I-I
of	I-I
student-to-student	I-I
responding	I-I
;	I-I
(	O
c	O
)	O
the	B-I
rotation	I-I
of	I-I
materials	I-I
every	I-I
5	I-I
minutes	I-I
during	I-I
the	I-I
30-minute	I-I
group	I-I
while	I-I
teaching	I-I
2	I-I
to	I-I
3	I-I
concepts	I-I
;	I-I
and	I-I
(	O
d	O
)	O
the	B-I
use	I-I
of	I-I
random	I-I
,	I-I
unpredictable	I-I
trials	I-I
for	I-I
student	I-I
responding	I-I
.	I-I


Migration	B-P
of	I-P
the	I-P
acetabular	I-P
component	I-P
:	I-P
effect	I-OUT
of	I-OUT
cement	I-OUT
pressurization	I-OUT
and	I-OUT
significance	I-OUT
of	I-OUT
early	I-OUT
radiolucency	I-OUT
:	I-OUT
a	O
randomized	O
5-year	O
study	O
using	O
radiostereometry	B-I
.	I-I


BACKGROUND	O
Cementing	O
technique	O
is	O
a	O
crucial	O
factor	O
in	O
prosthesis	B-P
fixation	I-P
.	I-P


Postoperative	O
radiolucent	B-OUT
lines	I-OUT
around	I-OUT
the	I-OUT
cup	I-OUT
were	I-OUT
correlated	I-OUT
to	I-OUT
later	I-OUT
RSA	I-OUT
results	I-OUT
.	I-OUT


Level	O
of	O
intervention	O
was	O
controlled	O
by	O
systematically	B-I
varying	I-I
the	I-I
manner	I-I
and	I-I
frequency	I-I
with	I-I
which	I-I
objects	I-I
were	I-I
presented	I-I
,	I-I
the	I-I
extent	I-I
to	I-I
which	I-I
the	I-I
experimenter	I-I
talked	I-I
to	I-I
the	I-I
infant	I-I
,	I-I
and	I-I
physical	I-I
proximity	I-I
.	I-I


Infant	O
attention	O
was	O
defined	O
as	O
duration	B-OUT
of	I-OUT
time	I-OUT
spent	I-OUT
examining	I-OUT
objects	I-OUT
.	I-OUT


Aftermath	O
of	O
a	O
clinical	O
trial	O
:	O
evaluating	O
the	O
sustainability	O
of	O
a	O
medical	B-I
device	I-I
intervention	I-I
in	I-P
Ghana	I-P
.	I-P


First-generation	O
trainees	O
scored	O
significantly	O
higher	O
than	O
second-generation	O
trainees	O
on	O
both	O
skills	B-OUT
and	I-OUT
knowledge	I-OUT
assessments	I-OUT
(	O
p	O
=	O
0.003	O
)	O
.	O


Protocolization	O
of	O
the	O
training	O
program	O
,	O
in	O
conjunction	O
with	O
skills	B-OUT
and	I-OUT
knowledge	I-OUT
assessment	O
,	O
may	O
improve	O
acquisition	B-OUT
and	I-OUT
retention	I-OUT
among	O
second-	O
and	O
future-generation	O
trainees	O
.	O


Consecutive	B-I
procedural	I-I
angiograms	I-I
of	I-P
patients	I-P
randomly	I-P
assigned	I-P
to	I-P
EES	I-I
(	I-P
n=669	I-P
)	I-P
or	I-I
PES	I-I
(	I-P
n=333	I-P
)	I-P
were	I-P
analysed	I-P
by	I-P
an	I-P
independent	I-P
angiographic	I-P
core	I-P
laboratory	I-P
.	I-P


Promoting	O
gynecologic	O
cancer	O
awareness	B-I
at	O
a	O
critical	O
juncture	O
--	O
where	O
women	O
and	O
providers	O
meet	O
.	O


BACKGROUND	O
Omeprazole	B-I
and	O
famotidine	B-I
both	O
reduce	O
severity	O
of	O
exercise-induced	B-OUT
gastritis	I-OUT
,	O
but	O
administering	O
famotidine	O
is	O
easier	O
than	O
administering	O
omeprazole	O
during	O
racing	O
competition	O
.	O


METHODS	O
Experiment	O
1	O
:	O
Equal	O
numbers	O
of	O
dogs	B-P
randomly	O
assigned	O
to	O
famotidine	B-I
(	O
20	O
mg	O
q24h	O
)	O
or	O
no	B-I
treatment	I-I
groups	O
.	O


Mucosal	B-OUT
appearance	I-OUT
was	O
blindly	O
scored	O
by	O
previously	O
described	O
scoring	O
system	O
.	O


CONCLUSIONS	O
AND	O
CLINICAL	O
RELEVANCE	O
Although	O
famotidine	O
provides	O
some	O
benefit	O
in	O
the	O
prevention	O
of	O
exercise-induced	B-OUT
gastric	I-OUT
lesions	I-OUT
,	O
omeprazole	O
is	O
superior	O
to	O
famotidine	O
in	O
preventing	O
gastritis	B-OUT
in	O
dogs	B-P
running	O
300	O
miles	O
.	O


Routine	O
administration	O
of	O
omeprazole	B-I
is	O
recommended	O
to	O
prevent	O
stress-associated	B-OUT
gastric	I-OUT
disease	I-OUT
in	O
exercising	B-P
and	I-P
racing	I-P
Alaskan	I-P
sled	I-P
dogs	I-P
.	I-P


Esomeprazole	B-I
resolves	O
chronic	B-OUT
heartburn	I-OUT
in	O
patients	B-P
without	I-P
erosive	I-P
oesophagitis	I-P
.	I-P


AIM	O
To	O
assess	O
the	O
efficacy	B-OUT
and	I-OUT
safety	I-OUT
of	O
esomeprazole	B-I
in	O
patients	B-P
with	I-P
frequent	I-OUT
heartburn	I-OUT
for	I-P
>	I-P
or	I-P
=	I-P
6	I-P
months	I-P
and	I-P
no	I-P
evidence	I-P
of	I-P
erosive	I-P
oesophagitis	I-P
on	I-P
endoscopy	I-P
.	I-P


Secondary	O
end-points	O
included	O
the	O
percentage	B-OUT
of	I-OUT
heartburn-free	I-OUT
days	I-OUT
and	I-OUT
the	I-OUT
time	I-OUT
to	I-OUT
first	I-OUT
and	I-OUT
sustained	I-OUT
resolution	I-OUT
of	I-OUT
heartburn	I-OUT
.	I-OUT


RESULTS	O
Patients	O
treated	O
with	O
either	O
dose	O
of	O
esomeprazole	B-I
were	O
two	O
to	O
three	O
times	O
more	O
likely	O
to	O
achieve	O
complete	B-OUT
resolution	I-OUT
of	I-OUT
heartburn	I-OUT
than	O
patients	O
treated	O
with	O
placebo	B-I
(	O
P	O
<	O
0.001	O
)	O
.	O


CONCLUSIONS	O
Esomeprazole	B-I
,	O
at	O
daily	O
doses	O
of	O
40	O
mg	O
or	O
20	O
mg	O
,	O
is	O
effective	B-OUT
and	I-OUT
safe	I-OUT
for	O
the	O
treatment	O
of	O
chronic	B-OUT
heartburn	I-OUT
in	O
patients	B-P
without	I-P
erosive	I-P
oesophagitis	I-P
.	I-P


The	O
results	O
are	O
discussed	O
with	O
respect	O
to	O
the	O
concept	B-OUT
of	I-OUT
illness	I-OUT
and	I-OUT
pain	I-OUT
as	O
a	O
setting	O
event	O
for	O
problem	O
behavior	O
.	O


The	O
need	O
for	O
research	O
to	O
develop	O
algorithms	O
that	O
allow	O
one	O
to	O
select	O
the	O
best	O
combination	O
of	O
medical	B-I
and	I-I
behavioral	I-I
interventions	I-I
for	O
specific	O
illnesses	O
and	O
contexts	O
is	O
noted	O
.	O


An	O
evaluation	O
of	O
chemical	O
arthrodesis	O
of	O
the	O
proximal	B-P
interphalangeal	I-P
joint	I-P
in	I-P
the	I-P
horse	I-P
by	O
using	O
monoiodoacetate	B-I
.	I-I


The	O
use	O
of	O
monoiodoacetate	B-I
(	I-I
MIA	I-I
)	I-I
for	O
arthrodesis	O
of	O
the	O
proximal	O
interphalangeal	O
joint	O
(	O
PIJ	O
)	O
and	O
the	O
effect	O
of	O
exercise	O
on	O
the	O
degree	O
of	O
fusion	O
were	O
investigated	O
.	O


Eight	B-P
horses	I-P
received	O
3	O
injections	O
(	O
Weeks	O
0	O
,	O
3	O
,	O
6	O
)	O
of	O
MIA	B-I
(	O
2	O
mL	O
;	O
60	O
mg/mL	O
)	O
into	O
the	O
right	O
or	O
left	O
front	O
PIJ	O
.	O


All	B-OUT
5	I-OUT
horses	I-OUT
showed	I-OUT
radiographic	I-OUT
evidence	I-OUT
of	I-OUT
bony	I-OUT
fusion	I-OUT
,	I-OUT
however	I-OUT
,	I-OUT
no	I-OUT
fusion	I-OUT
was	I-OUT
present	I-OUT
when	I-OUT
injected	I-OUT
joints	I-OUT
were	I-OUT
examined	I-OUT
on	I-OUT
postmortem	I-OUT
examination	I-OUT
.	I-OUT


INTRODUCTION	O
Current	O
evidence	O
suggests	O
that	O
Social	B-I
Stories	I-I
can	O
be	O
effective	O
in	O
tackling	O
problem	B-OUT
behaviours	I-OUT
exhibited	O
by	O
children	B-P
with	I-P
autism	I-P
spectrum	I-P
disorder	I-P
.	I-P


Case	O
reports	O
in	O
children	B-P
with	I-P
autism	I-P
have	O
suggested	O
that	O
these	O
stories	O
can	O
lead	O
to	O
a	O
number	O
of	O
benefits	O
including	O
improvements	O
in	O
social	B-OUT
interactions	I-OUT
and	I-OUT
choice	I-OUT
making	I-OUT
in	O
educational	O
settings	O
.	O


Participants	B-P
(	I-P
n=50	I-P
)	I-P
will	I-P
be	I-P
randomised	I-P
to	I-P
either	I-P
the	I-P
Social	I-I
Stories	I-I
intervention	I-I
or	I-I
a	I-I
comparator	I-I
group	I-I
where	I-P
they	I-P
will	I-P
be	I-P
read	I-P
standard	I-P
stories	I-P
for	I-P
an	I-P
equivalent	I-P
amount	I-P
of	I-P
time	I-P
.	I-P


Statistics	O
will	O
be	O
calculated	O
for	O
recruitment	B-OUT
rates	I-OUT
,	I-OUT
follow-up	I-OUT
rates	I-OUT
and	I-OUT
attrition	I-OUT
.	I-OUT


Qualitative	O
analysis	O
will	O
ascertain	O
information	O
on	O
perceptions	O
about	O
the	O
feasibility	B-OUT
and	I-OUT
acceptability	I-OUT
of	O
the	O
intervention	O
.	O


Humans	B-P
have	O
a	O
remarkable	O
ability	O
to	O
understand	O
spoken	O
language	O
despite	O
the	O
large	O
amount	O
of	O
variability	O
in	O
speech	O
.	O


Role	O
of	O
warm	B-I
saline	I-I
mouth	I-I
rinse	I-I
in	O
prevention	O
of	O
alveolar	B-OUT
osteitis	I-OUT
:	I-OUT
a	O
randomized	O
controlled	O
trial	O
.	O


BACKGROUND	O
The	O
present	O
study	O
was	O
aimed	O
at	O
determining	O
the	O
role	O
warm	B-I
saline	I-I
rinse	I-I
in	O
the	O
prevention	B-OUT
of	I-OUT
alveolar	I-OUT
osteitis	I-OUT
following	O
dental	O
extractions	O
.	O


MATERIALS	O
AND	O
METHODS	O
Apparently	O
patients	B-P
aged	I-P
16	I-P
and	I-P
above	I-P
who	I-P
were	I-P
referred	I-P
to	I-P
the	I-P
Oral	I-P
Surgery	I-P
Clinic	I-P
of	I-P
our	I-P
institution	I-P
,	I-P
with	I-P
an	I-P
indication	I-P
for	I-P
non-surgical	I-P
extraction	I-P
of	I-P
pathologic	I-P
teeth	I-P
were	O
prospectively	O
and	O
uniformly	O
randomized	O
into	O
warm	B-I
saline	I-I
group	I-I
and	O
control	B-I
.	I-I


The	O
experimental	B-P
group	I-P
(	I-P
n	I-P
=	I-P
80	I-P
)	I-P
were	O
instructed	O
to	O
gargle	B-I
6	I-I
times	I-I
daily	I-I
with	I-I
warm	I-I
saline	I-I
and	O
no	B-I
such	I-I
instructions	I-I
were	O
given	O
to	O
the	O
second	B-P
group	I-P
(	I-P
n	I-P
=	I-P
80	I-P
)	I-P
to	O
serve	O
as	O
controls	B-I
.	I-I


CONCLUSION	O
Warm	B-I
saline	I-I
mouth	I-I
rinse	I-I
instruction	O
is	O
beneficial	O
in	O
the	O
prevention	O
of	O
development	O
of	O
alveolar	B-OUT
osteitis	I-OUT
after	O
dental	O
extractions	O
.	O


Subjects/Study	O
interventions	O
:	O
Forty-one	B-P
(	I-P
41	I-P
)	I-P
patients	I-P
were	I-P
studied	I-P
.	I-P


CONCLUSIONS	O
Acupuncture	B-I
of	I-I
CV24	I-I
is	O
an	O
easy	O
to	O
apply	O
and	O
effective	O
method	O
to	O
reduce	O
gag	B-OUT
reflex	I-OUT
during	O
TEE	O
.	O


A	O
rigorous	O
statistical	O
method	O
of	O
scale	O
construction	O
consisting	O
of	O
a	O
modification	O
of	O
the	O
scale	O
discrimination	O
technique	O
was	O
employed	O
,	O
resulting	O
in	O
a	O
45-item	B-I
questionnaire	I-I
representing	O
three	O
orthogonally	O
derived	O
scales	O
.	O


The	O
Physiological	O
Tension	O
Scale	O
detected	O
significant	O
increases	O
in	O
tension	B-OUT
following	O
tension	O
inducement	O
,	O
whereas	O
the	O
Physical	O
Assessment	O
Scale	O
and	O
Cognitive	O
Tension	O
Scale	O
detected	O
increases	O
in	O
relaxation	B-OUT
following	O
relaxation	B-I
training	I-I
.	I-I


Randomized	O
trial	O
of	O
a	O
secondhand	B-I
smoke	I-I
exposure	I-I
reduction	I-I
intervention	I-I
among	O
hospital-based	B-P
pregnant	I-P
women	I-P
.	I-P


OBJECTIVE	O
This	O
study	O
sought	O
to	O
assess	O
the	O
effectiveness	B-OUT
of	O
a	O
secondhand	B-I
tobacco	I-I
smoke	I-I
(	I-I
SHS	I-I
)	I-I
prevention	I-I
program	I-I
based	O
on	O
an	O
expanded	O
Health	B-OUT
Belief	I-OUT
Model	I-OUT
(	O
HBM	O
)	O
incorporating	O
self-efficacy	O
among	O
pregnant	B-P
women	I-P
in	I-P
a	I-P
hospital	I-P
setting	I-P
in	I-P
Taiwan	I-P
.	I-P


METHODOLOGY	O
This	O
study	O
utilized	O
a	O
two-group	B-P
longitudinal	I-P
randomized	I-P
controlled	O
trial	O
design	O
.	O


Both	B-I
groups	I-I
were	I-I
given	I-I
questionnaires	I-OUT
as	I-I
a	I-I
pre-test	I-I
,	I-I
two	I-I
weeks	I-I
into	I-I
the	I-I
intervention	I-I
,	I-I
and	I-I
one	I-I
month	I-I
following	I-I
the	I-I
conclusion	I-I
of	I-I
the	I-I
intervention	I-I
.	I-I


CONCLUSIONS	O
These	O
results	O
should	O
encourage	O
health	O
professionals	O
to	O
educate	O
pregnant	B-P
women	I-P
regarding	O
the	O
harms	O
of	O
SHS	O
while	O
both	O
empowering	O
and	O
equipping	O
them	O
with	O
the	O
tools	O
to	O
confront	O
their	O
family	O
members	O
and	O
effectively	O
reduce	O
their	O
SHS	B-OUT
exposure	I-OUT
while	O
promoting	O
smoke-free	O
social	O
norms	O
.	O


BACKGROUND	O
AND	O
OBJECTIVE	O
This	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
efficacy	B-OUT
and	I-OUT
toxicity	I-OUT
of	O
monthly	O
alternating	O
ABVD/MOPP	B-I
compared	I-I
to	I-I
ABVD/OPP	I-I
regimens	O
in	O
patients	B-P
with	I-P
advanced	I-P
stage	I-P
Hodgkin	I-P
's	I-P
disease	I-P
(	I-P
HD	I-P
)	I-P
,	I-P
as	I-P
well	I-P
as	I-P
in	I-P
early	I-P
stage	I-P
patients	I-P
with	I-P
systemic	I-P
symptoms	I-P
and/or	I-P
bulky	I-P
disease	I-P
.	I-P


DESIGN	O
AND	O
METHODS	O
218	B-P
patients	I-P
with	I-P
previously	I-P
untreated	I-P
HD	I-P
entered	I-P
this	I-P
study	I-P
:	I-P
106	I-P
patients	I-P
in	I-P
arm	I-P
A	I-P
(	I-I
ABVD/MOPP	I-I
)	I-I
and	I-P
112	I-P
in	I-P
arm	I-P
B	I-P
(	I-I
ABVD/OPP	I-I
)	I-I
.	I-I


RESULTS	O
No	O
statistically	O
significant	O
differences	O
were	O
observed	O
between	O
the	O
two	O
arms	O
in	O
terms	O
of	O
CR	B-OUT
rate	I-OUT
and	I-OUT
toxicity	I-OUT
.	I-OUT


INTERPRETATION	O
AND	O
CONCLUSIONS	O
Both	O
schemes	O
of	O
chemotherapy	O
followed	O
by	O
radiotherapy	O
produce	O
high	O
percentages	O
of	O
CR	B-OUT
,	I-OUT
low	I-OUT
risk	I-OUT
of	I-OUT
relapse	I-OUT
and	I-OUT
an	I-OUT
acceptable	I-OUT
toxicity	I-OUT
.	I-OUT


METHODS	O
AND	O
MATERIALS	O
Toxicity	O
data	O
of	O
512	B-P
patients	I-P
(	I-P
conformally	I-P
treated	I-P
to	I-P
68	I-P
Gy	I-P
[	I-P
n	I-P
=	I-P
284	I-P
]	I-P
and	I-P
78	I-P
Gy	I-P
[	I-P
n	I-P
=	I-P
228	I-P
]	I-P
)	I-P
with	I-P
complete	I-P
follow-up	I-P
at	I-P
3	I-P
years	I-P
after	I-P
radiotherapy	I-I
were	I-P
studied	I-P
.	I-P


High	B-OUT
stool	I-OUT
frequency	I-OUT
fits	O
only	O
benefitted	O
significantly	O
(	O
p	O
=	O
0.003-0.006	O
)	O
from	O
the	O
inclusion	O
of	O
the	O
baseline	O
toxicity	O
score	O
.	O


The	O
primary	O
outcome	O
measure	O
was	O
recurrence	B-OUT
of	I-OUT
fits	I-OUT
.	I-OUT


The	O
recurrence	B-OUT
of	I-OUT
fits	I-OUT
and	O
other	B-OUT
maternal	I-OUT
complications	I-OUT
were	O
similar	B-OUT
in	O
the	O
two	O
groups	O
.	O


PoC	O
tests	O
measured	O
(	O
and	O
devices	O
used	O
)	O
in	O
the	O
trial	O
were	O
haemoglobin	B-OUT
A1c	I-OUT
and	I-OUT
urine	I-OUT
albumin	I-OUT
:	I-OUT
creatinine	I-OUT
ratio	I-OUT
(	I-OUT
DCA	I-OUT
2000	I-OUT
)	I-OUT
,	I-OUT
lipids	I-OUT
(	I-OUT
Cholestech	I-OUT
LDX	I-OUT
)	I-OUT
and	I-OUT
international	I-OUT
normalized	I-OUT
ratio	I-OUT
(	I-OUT
CoaguChek	I-OUT
S	I-OUT
)	I-OUT
.	I-OUT


Median	B-OUT
within-practice	I-OUT
imprecision	I-OUT
met	O
the	O
analytical	O
goals	O
for	O
all	O
PoC	O
tests	O
,	O
except	O
for	O
high-density	B-OUT
lipoprotein-cholesterol	I-OUT
(	I-OUT
HDL-C	I-OUT
)	I-OUT
where	O
observed	O
performance	O
was	O
outside	O
the	O
minimum	O
goal	O
for	O
one	O
level	O
and	O
one	O
lot	O
number	O
of	O
QC	O
.	O


Most	O
practices	O
achieved	O
the	O
imprecision	B-OUT
goals	O
for	O
all	O
analytes	O
,	O
with	O
the	O
principal	O
exception	O
of	O
HDL-C	B-OUT
.	I-OUT


RESULTS	O
CS	O
gel	O
was	O
safe	O
with	O
no	O
reported	O
severe	B-OUT
or	I-OUT
life-threatening	I-OUT
adverse	I-OUT
events	I-OUT
(	I-OUT
AE	I-OUT
)	I-OUT
.	I-OUT


The	O
majority	O
(	O
51	O
%	O
)	O
of	O
these	O
participants	O
reported	O
only	O
mild	B-OUT
events	I-OUT
.	I-OUT


Fewer	O
women	O
(	O
62	O
%	O
)	O
who	O
used	O
CS	O
experienced	O
urogenital	B-OUT
AE	I-OUT
than	O
those	O
assigned	O
to	O
placebo	B-I
gel	O
(	O
70	O
%	O
)	O
(	O
P	O
=	O
0.59	O
)	O
.	O


There	O
was	O
no	O
increase	O
in	O
AE	B-OUT
by	O
frequency	O
of	O
gel	O
use	O
or	O
sexual	O
activity	O
with	O
the	O
exception	O
of	O
abdominal/pelvic	B-OUT
pain	I-OUT
which	O
was	O
noted	O
more	O
frequently	O
with	O
twice	O
daily	O
use	O
among	O
sexually	O
abstinent	O
women	O
.	O


CONCLUSIONS	O
This	O
Phase	O
I	O
study	O
demonstrated	O
that	O
CS	B-I
vaginal	I-I
gel	I-I
was	O
safe	B-OUT
,	I-OUT
well	I-OUT
tolerated	I-OUT
and	I-OUT
acceptable	I-OUT
by	O
HIV-infected	B-P
women	I-P
and	I-P
their	I-P
male	I-P
partners	I-P
.	I-P


Detection	O
of	O
traumatic	O
arthrotomy	O
of	O
the	O
knee	O
using	O
the	O
saline	B-I
solution	I-I
load	I-I
test	I-I
.	I-I


RESULTS	O
The	O
study	O
group	O
included	O
thirty-one	B-P
female	I-P
patients	I-P
and	I-P
twenty-five	I-P
male	I-P
patients	I-P
with	I-P
a	I-P
combined	I-P
average	I-P
age	I-P
of	I-P
fifty	I-P
years	I-P
and	I-P
an	I-P
average	I-OUT
body	I-OUT
mass	I-OUT
index	I-OUT
of	I-P
30.9	I-P
.	I-P


There	O
was	O
no	B-OUT
correlation	I-OUT
between	I-OUT
necessary	I-OUT
injection	I-OUT
volume	I-OUT
and	I-OUT
sex	I-OUT
,	I-OUT
body	I-OUT
mass	I-OUT
index	I-OUT
,	I-OUT
or	I-OUT
knee	I-OUT
circumference	I-OUT
.	I-OUT


AIM	O
To	O
investigate	O
the	O
sustained	O
effect	O
on	O
quality	O
of	O
life	O
during	O
the	O
grass	O
pollen	O
season	O
1	O
year	O
after	O
3	O
years	O
of	O
treatment	O
with	O
the	O
SQ-standardized	O
grass	B-I
allergy	I-I
immunotherapy	I-I
tablet	I-I
(	I-I
AIT	I-I
)	I-I
,	O
Graza	O
(	O
Phleum	O
pratense	O
75,000	O
SQ-T/2800	O
BAU	O
;	O
ALK	O
,	O
Denmark	O
)	O
.	O


Subjects	B-P
received	O
3	O
years	O
of	O
grass	B-I
AIT	I-I
(	O
n	O
=	O
157	O
)	O
or	O
placebo	B-I
(	O
n	O
=	O
126	O
)	O
,	O
followed	O
by	O
1	O
year	O
of	O
follow-up	O
.	O


RESULTS	O
During	O
follow-up	O
,	O
the	O
overall	O
RQLQ	B-OUT
(	I-OUT
S	I-OUT
)	I-OUT
score	I-OUT
for	O
the	O
entire	O
grass	O
pollen	O
season	O
was	O
significantly	O
improved	O
in	O
the	O
active	O
group	O
(	O
relative	O
difference	O
to	O
placebo	B-I
:	I-I
23	O
%	O
,	O
P	O
=	O
0.004	O
)	O
.	O


Improvements	O
were	O
found	O
in	O
all	O
seven	O
RQLQ	B-OUT
(	I-OUT
S	I-OUT
)	I-OUT
domains	I-OUT
.	I-OUT


The	O
RQLQ	B-OUT
(	I-OUT
S	I-OUT
)	I-OUT
as	O
a	O
function	O
of	O
the	O
weekly	O
average	O
pollen	O
counts	O
showed	O
a	O
clear	O
separation	O
between	O
the	O
treatment	O
groups	O
(	O
P	O
<	O
0.001	O
)	O
.	O


Standard	O
Trauma	B-I
Focused	I-I
Cognitive	I-I
Behavioral	I-I
Therapy	I-I
may	O
be	O
insufficient	O
for	O
children	O
traumatized	O
by	O
exposure	O
to	O
interparental	O
violence	O
,	O
given	O
the	O
pervasive	O
impact	O
of	O
interparental	O
violence	O
on	O
the	O
family	O
system	O
.	O


HORIZON	O
is	O
a	O
trauma	B-I
focused	I-I
cognitive	I-I
behavioral	I-I
therapy	I-I
based	O
group	O
program	O
with	O
the	O
added	O
component	O
of	O
a	O
preparatory	B-I
parenting	I-I
program	I-I
aimed	O
at	O
improving	O
parental	O
availability	O
;	O
and	O
the	O
added	O
component	O
of	O
parent-child	O
sessions	O
to	O
improve	O
parent-child	O
interaction	O
.	O


To	O
address	O
this	O
secondary	O
aim	O
,	O
the	O
main	O
parameters	O
are	O
observational	O
and	O
questionnaire	O
measures	B-OUT
of	I-OUT
parental	I-OUT
availability	I-OUT
,	I-OUT
parent-child	I-OUT
relationship	I-OUT
variables	I-OUT
,	I-OUT
children	I-OUT
's	I-OUT
adjustment	I-OUT
problems	I-OUT
and	I-OUT
children	I-OUT
's	I-OUT
responses	I-OUT
to	O
interparental	O
violence	O
.	O


Perioperative	B-OUT
myocardial	I-OUT
infarctions	I-OUT
are	O
common	O
and	O
often	O
unrecognized	O
in	O
patients	B-P
undergoing	I-P
hip	I-P
fracture	I-P
surgery	I-P
.	I-P


BACKGROUND	O
The	O
aim	O
of	O
this	O
prospective	O
cohort	O
study	O
was	O
to	O
assess	O
the	O
incidence	O
and	O
characteristics	O
of	O
acute	O
myocardial	O
infarction	O
in	O
patients	B-P
undergoing	I-P
surgery	I-P
for	I-P
acute	I-P
hip	I-P
fracture	I-P
.	I-P


TnT	B-OUT
elevation	I-OUT
was	O
observed	O
in	O
36	O
patients	O
(	O
51	O
%	O
)	O
already	O
before	O
surgery	O
.	O


Seven	O
patients	O
(	O
10	O
%	O
)	O
had	O
ST	B-OUT
elevation	I-OUT
myocardial	I-OUT
infarction	I-OUT
,	O
23	O
patients	O
(	O
32	O
%	O
)	O
had	O
new	B-OUT
ST	I-OUT
depressions	I-OUT
,	O
and	O
21	O
patients	O
(	O
30	O
%	O
)	O
had	O
no	O
new	O
ST	O
segment	O
changes	O
in	O
the	O
serial	O
electrocardiographic	O
recordings	O
.	O


How	O
to	O
establish	O
equivalence	O
when	O
data	O
are	O
censored	O
:	O
a	O
randomized	B-P
trial	I-P
of	I-P
treatments	I-P
for	I-P
B	I-P
non-Hodgkin	I-P
lymphoma	I-P
.	I-P


An	O
equivalence	O
trial	O
of	O
maintenance	B-I
therapy	I-I
was	O
carried	O
out	O
in	O
children	B-P
with	I-P
B	I-P
non-Hodgkin	I-P
lymphoma	I-P
,	O
and	O
serves	O
as	O
an	O
illustration	O
.	O


There	O
were	O
four	B-I
randomised	I-I
treatment	I-I
phases	I-I
,	O
each	O
of	O
4	O
weeks	O
duration	O
.	O


Ambulatory	B-OUT
BP	I-OUT
was	O
performed	O
in	O
the	O
final	O
week	O
of	O
each	O
phase	O
.	O


There	O
was	O
a	O
dose-dependent	O
decrease	B-OUT
in	I-OUT
ambulatory	I-OUT
daytime	I-OUT
diastolic	I-OUT
and	I-OUT
mean	I-OUT
arterial	I-OUT
BP	I-OUT
with	O
the	O
progestogen	O
treatments	O
compared	O
with	O
placebo	O
(	O
P	O
<	O
0.05	O
)	O
.	O


The	O
authors	O
assessed	O
the	O
safety	B-OUT
and	O
effectiveness	B-OUT
of	O
atomoxetine	B-I
monotherapy	O
compared	O
with	O
combined	O
atomoxetine/fluoxetine	B-I
therapy	I-I
in	O
a	O
population	B-P
of	I-P
children	I-P
and	I-P
adolescents	I-P
with	I-P
ADHD	I-P
and	I-P
concurrent	I-P
symptoms	I-P
of	I-P
depression	I-P
or	I-P
anxiety	I-P
.	I-P


RESULTS	O
At	O
end	O
point	O
,	O
reductions	B-OUT
in	I-OUT
ADHD	I-OUT
,	I-OUT
depressive	I-OUT
,	I-OUT
and	I-OUT
anxiety	I-OUT
symptoms	I-OUT
were	O
marked	O
for	O
both	O
treatment	O
groups	O
(	O
p	O
<	O
.001	O
for	O
the	O
relevant	O
scale	O
in	O
each	O
symptom	O
cluster	O
)	O
.	O


CONCLUSIONS	O
In	O
pediatric	B-P
patients	I-P
with	I-P
ADHD	I-P
and	I-P
comorbid	I-P
symptoms	I-P
of	I-P
depression	I-P
or	I-P
anxiety	I-P
,	O
atomoxetine	B-I
monotherapy	I-I
appears	O
to	O
be	O
effective	O
for	O
treating	O
ADHD	O
.	O


Anxiety	B-OUT
and	I-OUT
depressive	I-OUT
symptoms	I-OUT
also	O
improved	O
,	O
but	O
the	O
absence	O
of	O
a	O
placebo-only	O
arm	O
does	O
not	O
allow	O
us	O
to	O
conclude	O
that	O
these	O
effects	O
are	O
specifically	O
the	O
result	O
of	O
treatment	O
with	O
atomoxetine	B-I
.	I-I


Double-blind	O
comparison	O
of	O
the	O
efficacy	B-OUT
and	I-OUT
safety	I-OUT
of	O
trandolapril	B-I
2	O
mg	O
and	O
hydrochlorothiazide	B-I
25	O
mg	O
in	O
patients	B-P
with	I-P
mild-to-moderate	I-P
essential	I-P
hypertension	I-P
.	I-P


This	O
multicenter	O
international	O
trial	O
recruited	O
205	B-P
patients	I-P
from	I-P
16	I-P
investigators	I-P
.	I-P


After	O
a	O
4-week	O
,	O
single-blind	B-I
placebo	I-I
run-in	O
,	O
patients	O
were	O
randomized	O
to	O
receive	O
16	O
weeks	O
of	O
trandolapril	B-I
2	O
mg/day	O
(	O
68	O
patients	O
)	O
,	O
hydrochlorothiazide	B-I
(	I-I
HCTZ	I-I
)	I-I
25	O
mg/day	O
(	O
68	O
patients	O
)	O
,	O
or	B-I
the	I-I
combination	I-I
(	O
69	O
patients	O
)	O
.	O


Intention-to-treat	O
analysis	O
showed	O
significant	O
decreases	O
in	O
all	O
three	O
groups	O
in	O
mean	O
(	O
+/-	O
SEM	O
)	O
supine	B-OUT
DBP	I-OUT
throughout	O
the	O
study	O
,	O
with	O
no	O
significant	O
differences	O
at	O
week	O
16	O
between	O
trandolapril	O
(	O
-10.6	O
+/-	O
1.3	O
mm	O
Hg	O
)	O
and	O
HCTZ	O
(	O
-10.9	O
+/-	O
1.3	O
mm	O
Hg	O
)	O
.	O


Blood	B-OUT
pressure	I-OUT
was	O
normalized	O
in	O
the	O
combination	O
group	O
in	O
67	O
%	O
of	O
patients	O
,	O
a	O
significantly	O
higher	O
proportion	O
than	O
either	O
trandolapril	O
(	O
63	O
%	O
)	O
or	O
HCTZ	O
(	O
60	O
%	O
;	O
p	O
=	O
0.04	O
)	O
.	O


PURPOSE	O
To	O
evaluate	O
the	O
effects	O
of	O
diltiazem	B-I
and	I-I
propranolol	I-I
in	O
patients	B-P
with	I-P
unstable	I-P
angina	I-P
.	I-P


A	O
coronary	B-I
arteriography	I-I
was	O
done	O
on	O
study	O
entry	O
.	O


RESULTS	O
A	O
significative	O
reduction	B-OUT
of	I-OUT
angina	I-OUT
crisis	I-OUT
number	I-OUT
,	I-OUT
duration	I-OUT
,	I-OUT
intensity	I-OUT
and	I-OUT
the	I-OUT
number	I-OUT
of	I-OUT
sublingual	I-OUT
nitrates	I-OUT
doses	I-OUT
were	O
observed	O
equally	O
in	O
both	O
groups	O
.	O


The	O
SAP	B-OUT
,	I-OUT
DAP	I-OUT
,	I-OUT
HR	I-OUT
and	I-OUT
RR	I-OUT
did	O
not	O
show	O
statistical	O
differences	O
between	O
groups	O
.	O


Individual	O
groups	O
analysis	O
showed	O
significative	O
reductions	B-OUT
of	O
SAP	B-OUT
,	I-OUT
DAP	I-OUT
and	I-OUT
HR	I-OUT
in	O
propranolol	B-I
group	O
.	O


The	O
CKMB	B-OUT
data	I-OUT
,	I-OUT
ECG	I-OUT
alterations	I-OUT
and	I-OUT
coronary	I-OUT
arteriography	I-OUT
characteristics	O
were	O
similar	O
.	O


Moisture-vapour-permeable	B-I
film	I-I
as	O
an	O
outpatient	B-P
burn	I-P
dressing	I-P
.	I-P


The	O
two	B-P
treatment	I-P
groups	I-P
were	I-P
closely	I-P
matched	I-P
in	I-P
age	I-P
,	I-P
sex	I-P
,	I-P
per	I-P
cent	I-P
of	I-P
BSA	I-P
burned	I-P
,	I-P
and	I-P
in	I-P
burn	I-P
severity	I-P
and	I-P
locations	I-P
.	I-P


The	O
clinical	B-OUT
infection	I-OUT
rate	I-OUT
and	I-OUT
time	I-OUT
to	I-OUT
healing	I-OUT
were	O
similar	O
in	O
both	O
groups	O
.	O


Patients	O
completed	O
a	O
questionnaire	B-I
before	O
and	O
1	O
year	O
after	O
surgery	O
to	O
evaluate	O
symptoms	O
,	O
function	O
,	O
and	O
overall	O
satisfaction	O
.	O


The	O
patients	O
in	O
the	O
SH	B-I
group	O
experienced	O
less	O
postoperative	B-OUT
pain/discomfort	I-OUT
as	O
scored	O
by	O
pain	B-OUT
during	I-OUT
bowel	I-OUT
movement	I-OUT
(	O
P	O
<	O
0.001	O
)	O
,	O
total	B-OUT
analgesic	I-OUT
requirement	I-OUT
over	I-OUT
the	I-OUT
first	I-OUT
3	I-OUT
days	I-OUT
(	O
according	O
to	O
the	O
World	O
Health	O
Organization	O
[	O
WHO	O
]	O
class	O
II	O
analgesics	O
[	O
P	O
=	O
0.002	O
]	O
;	O
class	O
III	O
[	O
P	O
=	O
0.066	O
]	O
)	O
,	O
and	O
per-patient	O
consumption	O
frequency	O
of	O
class	O
III	O
analgesics	O
(	O
P	O
=	O
0.089	O
)	O
.	O


A	O
clear	O
difference	O
in	O
morphine	B-OUT
requirement	I-OUT
became	O
evident	O
after	O
24	O
hours	O
(	O
P	O
=	O
0.010	O
)	O
.	O


Hospital	B-OUT
stay	I-OUT
was	O
significantly	O
shorter	O
in	O
the	O
SH	B-I
group	O
(	O
SH	O
2.2	O
+/-	O
1.2	O
[	O
0	O
;	O
5.0	O
]	O
versus	O
MM	B-I
3.1	O
+/-	O
1.7	O
[	O
1	O
;	O
8.0	O
]	O
P	O
<	O
0.001	O
)	O
.	O


CONCLUSION	O
Stapled	B-I
hemorrhoidopexy	I-I
causes	O
significantly	O
less	O
postoperative	B-OUT
pain	I-OUT
.	I-OUT


The	O
technique	O
is	O
reproducible	O
and	O
can	O
achieve	O
comparable	O
outcomes	B-OUT
as	O
those	O
of	O
the	O
MM	B-I
technique	O
as	O
long	O
as	O
the	O
well-described	O
steps	O
of	O
the	O
technique	O
are	O
followed	O
.	O


Its	O
effectiveness	B-OUT
in	O
relieving	O
symptoms	O
is	O
equivalent	O
to	O
conventional	O
surgery	O
,	O
and	O
the	O
number	B-OUT
of	I-OUT
hemorrhoidal	I-OUT
prolapse	I-OUT
recurrences	I-OUT
at	I-OUT
2	I-OUT
years	I-OUT
is	O
not	O
significantly	O
different	O
.	O


Hemorroidopexy	B-I
is	O
applicable	O
for	O
treating	O
reducible	O
hemorrhoidal	O
prolapse	O
.	O


In	O
this	O
study	O
we	O
examined	O
the	O
social	O
behaviors	O
of	O
4-	B-P
to	I-P
12-year-old	I-P
children	I-P
with	I-P
autism	I-P
spectrum	I-P
disorders	I-P
(	I-P
ASD	I-P
;	I-P
N	I-P
=	I-P
24	I-P
)	I-P
during	O
three	O
tradic	O
interactions	O
with	O
an	B-I
adult	I-I
confederate	I-I
and	I-I
an	I-I
interaction	I-I
partner	I-I
,	O
where	O
the	O
interaction	O
partner	O
varied	O
randomly	O
among	O
(	B-I
1	I-I
)	I-I
another	I-I
adult	I-I
human	I-I
,	I-I
(	I-I
2	I-I
)	I-I
a	I-I
touchscreen	I-I
computer	I-I
game	I-I
,	I-I
and	I-I
(	I-I
3	I-I
)	I-I
a	I-I
social	I-I
dinosaur	I-I
robot	I-I
.	O


The	O
median	B-OUT
neutrophil	I-OUT
count	I-OUT
at	O
14	O
days	O
was	O
significantly	O
higher	O
in	O
the	O
GM	B-I
CSF	I-I
group	O
(	O
1.90	O
vs.	O
0.46	O
x	O
10	O
(	O
9	O
)	O
/l	O
)	O
.	O


Tumor	B-OUT
budding	I-OUT
is	O
an	O
independent	O
predictor	O
of	O
outcome	O
in	O
AJCC/UICC	B-P
stage	I-P
II	I-P
colorectal	I-P
cancer	I-P
.	I-P


For	O
multivariable	B-I
analysis	I-I
,	O
Cox	O
's	O
proportional	O
hazards	O
regression	O
models	O
were	O
performed	O
.	O


Cox	O
's	O
proportional	O
hazards	O
regression	O
models	O
proved	O
tumor	B-I
budding	I-I
to	O
be	O
an	O
independent	O
predictor	O
of	O
disease	B-OUT
progression	I-OUT
(	O
hazard	O
ratio	O
3.91	O
,	O
95	O
%	O
confidence	O
interval	O
1.3-11.77	O
;	O
P	O
=	O
0.02	O
)	O
and	B-OUT
cancer-related	I-OUT
death	I-OUT
(	O
hazard	O
ratio	O
5.90	O
,	O
95	O
%	O
confidence	O
interval	O
1.62-21.51	O
;	O
P	O
=	O
0.007	O
)	O
.	O


Early	O
versus	O
late	O
hCG	B-I
administration	I-I
to	O
trigger	O
ovulation	O
in	O
mild	O
stimulated	O
IUI	O
cycles	O
:	O
a	O
randomized	O
clinical	O
trial	O
.	O


OBJECTIVES	O
To	O
verify	O
non-inferiority	O
of	O
the	O
clinical	O
pregnancy	O
rate	O
of	O
Early	B-I
hCG	I-I
administration	I-I
(	O
leading	O
follicle	O
sizes	O
within	O
16.0-16.9	O
mm	O
in	O
diameter	O
)	O
compared	O
to	O
Late	B-I
hCG	I-I
administration	I-I
(	O
leading	O
follicle	O
sizes	O
within	O
18.0-18.9	O
mm	O
in	O
diameter	O
)	O
.	O


Six	B-P
hundred	I-P
and	I-P
twelve	I-P
infertile	I-P
women	I-P
candidates	I-P
for	I-P
intrauterine	I-P
insemination	I-P
(	I-P
IUI	I-P
)	I-P
received	O
HP-hMG	B-I
75	O
IU/day	O
SC	O
from	O
cycle	O
days	O
4	O
to	O
8	O
and	O
then	O
as	O
per	O
ovarian	O
response	O
.	O


Ovulation	O
was	O
randomly	O
triggered	O
(	O
hCG	O
5000	O
IU	O
,	O
IM	O
)	O
when	O
the	O
leading	O
follicle	O
diameter	O
ranged	O
between	O
either	O
16.0	O
and	O
16.9	O
mm	O
(	O
Early	O
hCG	B-I
group	O
,	O
n=227	O
)	O
or	O
18.0	O
and	O
18.9	O
mm	O
(	O
Late	O
hCG	O
group	O
,	O
n=207	O
)	O
and	O
IUI	O
was	O
performed	O
approximately	O
36	O
h	O
later	O
.	O


Clinical	O
(	O
11.9	O
%	O
versus	O
12.1	O
%	O
)	O
and	O
ongoing	O
(	O
11.0	O
%	O
versus	O
8.6	B-OUT
%	I-OUT
)	I-OUT
pregnancy	I-OUT
rates	I-OUT
per	O
randomized	B-P
women	I-P
were	O
similar	O
in	O
the	O
two	O
groups	O
and	O
statistical	O
non-inferiority	O
of	B-OUT
clinical	I-OUT
and	I-OUT
ongoing	I-OUT
pregnancy	I-OUT
rates	O
was	O
demonstrated	O
.	O


CONCLUSION	O
These	O
results	O
suggest	O
that	B-I
hCG	I-I
administered	O
when	O
the	O
largest	O
follicle	O
size	O
reaches	O
16.0-16.9	O
mm	O
leads	O
to	O
similar	O
clinical	O
and	O
ongoing	O
pregnancy	O
rates	O
as	O
when	O
it	O
reaches	O
18.0-18.9	O
mm	O
in	O
IUI	O
cycles	O
.	O


Managing	O
repetitive	O
behaviours	O
in	O
young	B-P
children	I-P
with	I-P
autism	I-P
spectrum	I-P
disorder	I-P
(	I-P
ASD	I-P
)	I-P
:	I-P
pilot	O
randomised	O
controlled	O
trial	O
of	O
a	O
new	O
parent	B-P
group	O
intervention	O
.	O


We	O
report	O
the	O
acceptability	O
,	O
feasibility	O
and	O
impact	O
on	O
child	O
functioning	O
of	O
a	O
new	O
8	B-I
weeks	I-I
parent-group	I-I
intervention	I-I
to	I-I
manage	I-I
restricted	I-I
and	I-I
repetitive	I-I
behaviours	I-I
(	I-P
RRB	I-P
)	I-P
in	I-P
young	I-P
children	I-P
with	I-P
ASD	I-P
aged	I-P
3-7	I-P
years	I-P
.	I-P


Fidelity	B-OUT
of	I-OUT
delivery	I-OUT
was	I-OUT
high	I-OUT
,	I-OUT
and	I-OUT
attendance	I-OUT
was	O
90	O
%	O
.	O


BACKGROUND	O
In	O
1998	O
,	O
mandatory	O
folic	O
acid	O
fortification	O
of	O
white	B-I
flour	I-I
and	I-I
select	I-I
cereal	I-I
grain	I-I
products	I-I
was	O
implemented	O
in	O
Canada	B-P
with	O
the	O
intention	O
to	O
increase	O
dietary	B-I
folate	I-I
intakes	I-I
of	O
reproducing	B-P
women	I-P
.	I-P


The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
how	O
predictive	O
blood	B-OUT
folate	I-OUT
concentrations	I-OUT
and	I-OUT
folate	I-OUT
intakes	I-OUT
are	O
of	O
each	O
other	O
in	O
a	O
sample	O
of	O
well-educated	B-P
lactating	I-P
Canadian	I-P
women	I-P
exposed	I-P
to	I-P
high	I-P
levels	I-P
of	I-P
synthetic	I-P
folate	I-P
.	I-P


RESULTS	O
Median	O
blood	B-OUT
folate	I-OUT
concentrations	I-OUT
of	O
all	O
participants	O
were	O
well	O
above	O
plasma	O
and	O
RBC	O
folate	O
cut-off	O
levels	O
indicative	O
of	O
deficiency	O
(	O
6.7	O
and	O
317	O
nmol/L	O
,	O
respectively	O
)	O
and	O
all	O
,	O
except	O
for	O
2	O
subjects	O
,	O
were	O
above	O
the	O
cut-off	O
for	O
NTD-risk	O
reduction	O
(	O
>	O
906	O
nmol/L	O
)	O
.	O


Only	O
modest	O
associations	O
existed	O
between	O
total	B-OUT
folate	I-OUT
intakes	I-OUT
and	O
plasma	B-OUT
(	O
r	O
=	O
0.46	O
,	O
P	O
<	O
0.001	O
)	O
and	O
RBC	O
(	O
r	O
=	O
0.36	O
,	O
P	O
<	O
0.01	O
)	O
folate	B-OUT
concentrations	I-OUT
at	O
16-wk	O
postpartum	O
.	O


CONCLUSION	O
Folate	B-OUT
intakes	I-OUT
,	O
estimated	O
by	O
food	O
composition	O
tables	O
,	O
and	O
blood	B-OUT
folate	I-OUT
concentrations	I-OUT
are	O
not	O
predictive	O
of	O
each	O
other	O
in	O
Canadian	O
lactating	O
women	O
exposed	O
to	O
high	O
levels	O
of	O
folate	B-OUT
.	I-OUT


Clinical	O
and	O
radiographic	O
evaluation	O
of	O
guided	O
tissue	O
regeneration	O
in	O
the	O
treatment	O
of	O
class	B-P
II	I-P
furcation	I-P
defects	I-P
.	I-P


PURPOSE	O
To	O
evaluate	O
the	O
treatment	O
outcomes	B-OUT
after	O
guided	B-I
tissue	I-I
regeneration	I-I
(	I-I
GTR	I-I
)	I-I
with	O
a	O
bioabsorbable	O
membrane	O
in	O
Class	B-P
II	I-P
furcation	I-P
defects	I-P
in	O
mandibular	O
molars	O
.	O


METHODS	O
Nine	B-P
patients	I-P
,	I-P
with	I-P
two	I-P
comparable	I-P
Class	I-P
II	I-P
furcation	I-P
defects	I-P
were	I-P
included	I-P
in	I-P
the	I-P
study	I-P
.	I-P


Comparing	O
the	O
two	O
treatments	O
,	O
no	O
statistically	O
significant	O
differences	O
were	O
found	O
in	O
PD	B-OUT
reduction	I-OUT
(	O
GTR	O
:	O
1.67	O
mm	O
;	O
OFD	O
:	O
2.51	O
mm	O
,	O
P	O
=	O
0.26	O
)	O
,	O
CAL-v	B-OUT
gain	I-OUT
(	O
GTR	O
:	O
0.62	O
mm	O
;	O
OFD	O
:	O
1.16	O
mm	O
,	O
P=	O
0.37	O
)	O
,	O
and	O
GR	B-OUT
increase	I-OUT
(	O
GTR	O
:	O
1.04	O
mm	O
;	O
OFD	O
:	O
1.24	O
mm	O
,	O
P	O
=	O
0.31	O
)	O
.	O


GTR	B-I
provided	O
complete	O
closure	B-OUT
of	I-OUT
the	I-OUT
furcation	I-OUT
defect	I-OUT
in	O
two	O
sites	O
and	O
superior	B-OUT
horizontal	I-OUT
clinical	I-OUT
attachment	I-OUT
level	I-OUT
gain	I-OUT
(	O
GTR	O
:	O
2.27	O
mm	O
;	O
OFD	O
:	O
1.01	O
mm	O
,	O
P	O
=	O
0.05	O
)	O
.	O


In	O
order	O
to	O
identify	O
healthcare	B-OUT
resource	I-OUT
use	I-OUT
patterns	I-OUT
associated	O
with	O
chronic	B-P
obstructive	I-P
pulmonary	I-P
disease	I-P
(	I-P
COPD	I-P
)	I-P
,	O
resource	O
utilization	O
(	O
RU	O
)	O
data	O
collection	O
was	O
integrated	O
into	O
a	O
randomized	O
,	O
double-blind	O
placebo-controlled	B-I
study	O
of	O
Viozan	O
(	O
sibenadet	O
HCl	O
)	O
.	O


Subsequent	O
data	O
were	O
collected	O
by	O
means	O
of	O
an	O
Interactive	B-OUT
Voice	I-OUT
Response	I-OUT
System	I-OUT
(	I-OUT
IVRS	I-OUT
)	I-OUT
at	O
30-day	O
intervals	O
(	O
14	O
time	O
points	O
)	O
during	O
the	O
study	O
and	O
in	O
the	O
follow-up	O
period	O
.	O


Physicians	O
were	O
seen	O
to	O
be	O
the	O
most	O
common	O
source	O
of	O
care	O
for	O
patients	O
with	O
COPD	O
and	O
more	O
of	O
the	O
patients	B-P
with	I-P
severe	I-P
COPD	I-P
(	I-P
stage	I-P
III	I-P
)	I-P
than	I-P
mild	I-P
(	I-P
stage	I-P
I	I-P
)	I-P
were	O
seen	O
to	O
utilize	O
the	O
most	O
expensive	O
resources	O
(	O
e.g	O
.	O


This	O
study	O
has	O
shown	O
that	O
use	O
of	O
an	O
IVRS	O
,	O
even	O
in	O
elderly	B-P
patients	I-P
,	O
is	O
an	O
effective	O
means	O
of	O
gathering	O
RU	O
data	O
over	O
long	O
periods	O
.	O


Beliefs	B-I
underlying	O
the	O
intention	O
to	O
donate	O
again	O
among	O
first-time	B-P
blood	I-P
donors	I-P
who	I-P
experience	I-P
a	I-P
mild	I-P
adverse	I-P
event	I-P
.	I-P


The	O
findings	O
provide	O
insight	O
into	O
those	O
messages	B-I
that	O
could	O
be	O
communicated	O
via	O
the	O
mass	O
media	O
or	O
in	O
targeted	O
communications	O
to	O
retain	O
first-time	B-P
donors	I-P
who	O
have	O
experienced	O
a	O
mild	O
vasovagal	O
reaction	O
.	O


[	O
Initial	O
nuclear	B-I
magnetic	I-I
resonance	I-I
tomography	I-I
results	O
of	O
the	O
treatment	B-P
course	I-P
of	I-P
avascular	I-P
femur	I-P
head	I-P
necrosis	I-P
after	I-P
femoral	I-P
core	I-P
decompression	I-P
]	I-P
.	I-P


The	O
vascular	B-P
femoral	I-P
head	I-P
necrosis	I-P
is	I-P
a	I-P
serious	I-P
illness	I-P
,	I-P
especially	I-P
when	I-P
appearing	I-P
in	I-P
patients	I-P
aged	I-P
30	I-P
to	I-P
50	I-P
years	I-P
.	I-P


Many	O
etiologic	O
factors	O
cause	O
a	O
femoral	O
head	O
necrosis	O
such	O
as	O
,	O
for	O
example	O
,	O
high-dose	B-P
steroids	I-P
,	I-P
abuse	I-P
of	I-P
alcohol	I-P
,	I-P
defect	I-P
of	I-P
bone	I-P
marrow	I-P
and	I-P
trauma	I-P
of	I-P
the	I-P
hip	I-P
.	I-P


The	O
stage	O
IIc	O
and	O
III	O
shows	O
an	O
evident	O
enhancement	O
in	O
contrast	O
media	O
in	O
MRI	B-I
.	I-I


The	O
evaluation	O
of	O
the	O
signal	O
intensity	O
by	O
the	O
dynamic	B-OUT
screening	I-OUT
sequence	I-OUT
is	O
considered	O
as	O
an	O
objective	O
contribution	O
for	O
the	O
staging	B-OUT
of	I-OUT
the	I-OUT
femoral	I-OUT
head	I-OUT
necrosis	I-OUT
.	I-OUT


This	O
enables	O
one	O
to	O
differentiate	O
between	B-P
the	I-P
curable	I-OUT
stage	I-OUT
IIc	I-OUT
and	I-P
the	I-P
stage	I-OUT
III	I-OUT
,	I-P
showing	I-P
the	I-P
beginning	I-P
of	I-P
breakdown	I-OUT
of	I-OUT
the	I-OUT
femoral	I-OUT
head	I-OUT
.	I-OUT


Aminocaproic	B-I
acid	I-I
versus	O
prednisone	B-I
for	O
the	O
treatment	O
of	O
traumatic	B-P
hyphema	I-P
.	I-P


One	B-P
hundred	I-P
twelve	I-P
patients	I-P
who	I-P
sustained	I-P
hyphema	I-P
after	I-P
blunt	I-P
trauma	I-P
were	I-P
enrolled	I-P
in	O
a	O
double-blind	O
randomized	O
clinical	O
trial	O
to	O
determine	O
the	O
relative	O
efficacies	O
of	O
aminocaproic	B-I
acid	I-I
(	I-I
Amicar	I-I
)	I-I
and	O
systemic	B-I
prednisone	I-I
for	O
reducing	O
the	O
rate	B-OUT
of	I-OUT
secondary	I-OUT
hemorrhage	I-OUT
.	I-OUT


Sun	B-I
protection	I-I
behaviors	I-I
and	O
stages	O
of	O
change	O
for	O
the	O
primary	O
prevention	O
of	O
skin	B-P
cancers	I-P
among	I-P
beachgoers	I-P
in	I-P
southeastern	I-P
New	I-P
England	I-P
.	I-P


METHODS	O
Before	O
the	O
experiment	O
,	O
72	B-P
rats	I-P
were	I-P
randomly	I-P
allocated	I-P
to	I-P
receive	I-P
HBO	I-I
or	I-I
air	I-I
treatment	I-I
.	I-I


SnPP	O
,	O
on	O
the	O
contrary	O
,	O
offset	O
the	O
effects	O
of	O
HBO	B-I
and	O
worsened	O
the	O
LPS-induced	O
lung	O
injury	O
.	O


Furthermore	O
,	O
this	O
HBO	B-I
attenuation	O
of	O
iNOS	O
expression	O
involves	O
HO-1	O
induction	O
.	O


OBJECTIVE	O
One-third	O
of	O
the	O
total	O
population	O
seems	O
to	O
develop	O
minor	O
recurrent	B-P
aphthous	I-P
stomatitis	I-P
(	I-P
RAS	I-P
)	I-P
during	O
their	O
lifetime	O
.	O


The	O
objective	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
whether	O
the	O
prevalence	O
of	O
RAS	O
decreased	O
with	O
perilla	B-I
oil	I-I
(	O
rich	O
in	O
alpha-linolenic	O
acid	O
)	O
.	O


METHODS	O
Thirty	B-P
subjects	I-P
(	I-P
8	I-P
men	I-P
and	I-P
22	I-P
women	I-P
)	I-P
who	I-P
had	I-P
minor	I-P
RAS	I-P
at	I-P
least	I-P
once	I-P
a	I-P
month	I-P
were	O
randomly	O
allocated	O
to	O
a	O
soybean	B-I
oil	I-I
group	I-I
or	I-I
a	I-I
perilla	I-I
oil	I-I
group	I-I
in	I-I
a	I-I
double-blind	I-I
manner	I-I
(	I-I
experimental	I-I
phase	I-I
)	I-I
after	I-I
a	I-I
run-in	I-I
phase	I-I
of	I-I
4	I-I
mo	I-I
during	I-I
which	I-I
subjects	I-I
used	I-I
a	I-I
reference	I-I
oil	I-I
,	I-I
the	I-I
most	I-I
popular	I-I
cooking	I-I
oil	I-I
in	I-I
Japan	I-I
,	I-I
or	I-I
a	I-I
50/50	I-I
mixture	I-I
of	I-I
soybean	I-I
oil	I-I
and	I-I
rapeseed	I-I
oil	I-I
.	I-I


Occurrence	B-OUT
and	I-OUT
needed	I-OUT
days	I-OUT
for	I-OUT
healing	I-OUT
of	I-OUT
minor	I-OUT
RAS	I-OUT
were	O
recorded	O
during	O
the	O
two	O
phases	O
and	O
compared	O
.	O


The	O
effect	O
of	O
cessation	O
of	O
raloxifene	B-I
treatment	O
on	O
bone	B-P
turnover	I-P
in	I-P
postmenopausal	I-P
women	I-P
.	I-P


The	O
effect	O
of	O
cessation	O
of	O
raloxifene	B-I
therapy	O
on	O
bone	O
turnover	O
is	O
unknown	O
.	O


Our	O
aim	O
was	O
to	O
determine	O
the	O
effect	O
of	O
cessation	O
of	O
raloxifene	B-I
treatment	O
on	O
bone	B-OUT
turnover	I-OUT
and	O
bone	B-OUT
mineral	I-OUT
density	I-OUT
(	I-OUT
BMD	I-OUT
)	I-OUT
in	O
postmenopausal	B-P
,	I-P
osteopenic	I-P
women	I-P
.	I-P


Women	B-P
aged	I-P
50	I-P
to	I-P
80	I-P
years	I-P
received	O
raloxifene	B-I
for	O
96	O
weeks	O
and	O
were	O
then	O
randomized	O
to	O
continue	O
raloxifene	B-I
(	I-P
group	I-P
1	I-P
,	I-P
n=20	I-P
)	I-P
or	I-I
placebo	I-I
(	I-P
group	I-P
2	I-P
,	I-P
n=20	I-P
)	I-P
for	I-P
a	I-P
further	I-P
96	I-P
weeks	I-P
.	I-P


Continuation	O
of	O
raloxifene	B-I
(	O
group	O
1	O
)	O
maintained	O
these	O
changes	O
.	O


Following	O
cessation	O
of	O
raloxifene	B-I
(	O
group	O
2	O
)	O
,	O
bone	B-OUT
markers	I-OUT
returned	O
to	O
baseline	O
levels	O
(	O
by	O
120	O
weeks	O
)	O
.	O


Bone	B-OUT
loss	I-OUT
following	O
cessation	O
of	O
raloxifene	B-I
therapy	O
at	O
96	O
weeks	O
was	O
greater	O
than	O
in	O
the	O
control	O
group	O
,	O
suggesting	O
accelerated	B-P
bone	I-P
loss	I-P
.	I-P


The	O
beneficial	O
effect	O
on	O
bone	B-OUT
turnover	I-OUT
of	O
96	O
weeks	O
of	O
raloxifene	O
was	O
lost	O
6	O
months	O
after	O
cessation	O
of	O
treatment	O
.	O


Effects	O
of	O
hydraulic	O
circuit	O
training	O
on	O
cardiovascular	B-P
function	I-P
.	I-P


Maximal	B-OUT
aerobic	I-OUT
power	I-OUT
(	I-OUT
VO2max	I-OUT
)	I-OUT
,	I-OUT
with	I-OUT
simultaneous	I-OUT
measurement	I-OUT
of	I-OUT
stroke	I-OUT
volume	I-OUT
(	I-OUT
SV	I-OUT
)	I-OUT
and	I-OUT
cardiac	I-OUT
output	I-OUT
(	I-OUT
CO	I-OUT
)	I-OUT
,	I-OUT
by	I-OUT
impedance	I-OUT
cardiography	I-OUT
,	O
was	O
assessed	O
pre-	O
and	O
post-training	O
.	O


Following	O
training	O
VO2max	B-OUT
(	I-OUT
ml.kg-1	I-OUT
min-1	I-OUT
)	I-OUT
was	O
significantly	O
increased	O
in	O
all	O
training	O
groups	O
(	O
18.0	O
,	O
12.5	O
,	O
and	O
11.3	O
%	O
for	O
cycle	O
,	O
HCTsub	O
,	O
and	O
HCTmax	B-OUT
groups	I-OUT
,	O
respectively	O
;	O
P	O
less	O
than	O
0.05	O
)	O
.	O


These	O
findings	O
suggest	O
that	O
both	O
maximal	O
and	O
submaximal	O
HCT	O
programs	O
can	O
elicit	O
improvements	O
in	O
cardiovascular	B-OUT
fitness	I-OUT
.	I-OUT


In	O
all	O
3	O
conditions	O
,	O
LF/HF	B-OUT
ratio	I-OUT
decreased	O
from	O
Baseline	O
to	O
Heel	O
Stick	O
and	O
increased	O
to	O
Recovery	O
;	O
no	O
differences	O
were	O
found	O
between	O
IC	B-I
and	O
two	O
KC	B-I
conditions	O
.	O


PERSPECTIVE	O
This	O
study	O
showed	O
that	O
KC	B-I
has	O
a	O
significant	O
effect	O
on	O
reducing	O
autonomic	O
pain	O
responses	O
in	O
preterm	B-P
infants	I-P
.	I-P


In	B-P
2003	I-P
50	I-P
patients	I-P
treated	I-P
with	I-P
one	I-I
or	I-I
two	I-I
epidural	I-I
injections	I-I
have	I-P
been	I-P
selected	I-P
"	I-P
ad	I-P
random	I-P
"	I-P
and	I-P
50	I-P
patients	I-P
treated	I-P
with	I-P
disc	I-I
coablation	I-I
.	I-I


Finally	O
,	O
average	B-OUT
VAS	I-OUT
was	O
clearly	O
lower	O
(	O
p	O
<	O
0.01	O
)	O
after	O
coablation	O
as	O
compared	O
to	O
epidural	B-I
injections	I-I
.	O


This	O
result	O
revealed	O
that	O
acupuncture	B-I
seemed	O
to	O
have	O
more	O
affect	O
on	O
OKT4+	B-OUT
cells	I-OUT
than	O
on	O
OKT8+	B-OUT
cells	I-OUT
.	I-OUT


From	O
our	O
study	O
we	O
believe	O
that	O
acupuncture	B-I
can	O
be	O
used	O
as	O
one	O
of	O
the	O
many	O
treatments	O
for	O
patients	B-P
with	I-P
cancer	I-P
.	I-P


PURPOSE	O
This	O
randomized	O
group	O
experiment	O
compared	O
the	O
efficacy	O
of	O
2	O
communication	B-I
interventions	I-I
(	I-I
Responsive	I-I
Education	I-I
and	I-I
Prelinguistic	I-I
Milieu	I-I
Teaching	I-I
[	I-I
RPMT	I-I
]	I-I
and	I-I
the	I-I
Picture	I-I
Exchange	I-I
Communication	I-I
System	I-I
[	I-I
PECS	I-I
]	I-I
)	I-I
on	O
spoken	O
communication	O
in	O
36	B-P
preschoolers	I-P
with	I-P
autism	I-P
spectrum	I-P
disorders	I-P
(	I-P
ASD	I-P
)	I-P
.	I-P


RESULTS	O
PECS	B-OUT
was	I-OUT
more	I-OUT
successful	I-OUT
than	I-OUT
RPMT	I-OUT
in	I-OUT
increasing	I-OUT
the	I-OUT
number	I-OUT
of	I-OUT
nonimitative	I-OUT
spoken	I-OUT
communication	I-OUT
acts	I-OUT
and	I-OUT
the	I-OUT
number	I-OUT
of	I-OUT
different	I-OUT
nonimitative	I-OUT
words	I-OUT
used	I-OUT
at	I-OUT
the	I-OUT
posttreatment	I-OUT
period	I-OUT
.	I-OUT


Considering	O
growth	O
over	O
all	O
3	O
measurement	O
periods	O
,	O
an	O
exploratory	O
analysis	O
showed	O
that	O
growth	B-OUT
rate	I-OUT
of	I-OUT
the	I-OUT
number	I-OUT
of	I-OUT
different	I-OUT
nonimitative	I-OUT
words	I-OUT
was	I-OUT
faster	I-OUT
in	I-OUT
the	I-OUT
PECS	I-OUT
group	O
than	O
in	O
the	O
RPMT	O
group	O
for	O
children	O
who	O
began	O
treatment	O
with	O
relatively	O
high	O
object	O
exploration	O
.	O


In	O
contrast	O
,	O
analogous	B-OUT
slopes	I-OUT
were	O
steeper	O
in	O
the	O
RPMT	O
group	O
than	O
in	O
the	O
PECS	O
group	O
for	O
children	O
who	O
began	O
treatment	O
with	O
relatively	O
low	O
object	O
exploration	O
.	O


All	O
cavities	B-P
received	O
the	O
same	O
adhesive	O
system	O
and	O
were	O
restored	O
with	O
flowable	O
composite	O
according	O
to	O
manufacturer	O
's	O
instructions	O
.	O


Teeth	O
were	O
submitted	O
to	O
thermal	B-I
cycling	I-I
and	O
immersed	O
in	O
50	O
%	O
silver	B-I
nitrate	I-I
solutions	I-I
for	O
8	O
h	O
in	O
total	O
darkness	O
.	O


CONCLUSIONS	O
It	O
can	O
be	O
concluded	O
that	O
no	O
significant	O
difference	O
was	O
noted	O
between	O
the	O
two	O
types	O
of	O
enamel	B-I
preparation	I-I
when	O
etching	O
was	O
performed	O
.	O


Dexmedetomidine	B-I
pretreatment	O
alleviates	O
propofol	B-P
injection	I-P
pain	I-P
.	I-P


METHODS	O
Patients	B-P
undergoing	I-P
elective	I-P
surgical	I-P
procedures	I-P
were	I-P
randomly	I-P
allocated	I-P
into	I-P
seven	I-P
groups	I-P
of	I-P
30	I-P
patients	I-P
each	I-P
.	I-P


Patients	O
in	O
groups	O
V	O
,	O
VI	O
,	O
and	O
VII	O
received	B-I
DEX	I-I
as	I-I
above	I-I
,	I-I
but	I-I
5	I-I
minutes	I-I
before	I-I
propofol	I-I
injection	I-I
.	I-I


There	O
were	O
no	O
differences	O
in	O
either	B-OUT
mean	I-OUT
arterial	I-OUT
pressure	I-OUT
or	I-OUT
heart	I-OUT
rate	I-OUT
at	O
any	O
time	O
point	O
after	B-I
DEX	O
injection	O
among	O
the	O
groups	O
.	O


CONCLUSIONS	O
Pretreatment	O
with	O
intravenous	B-I
DEX	O
1	O
µg/kg	O
5	O
min	O
prior	O
to	O
injection	O
of	O
long-chain	O
triglyceride	O
propofol	O
is	O
effective	O
and	O
safe	O
in	O
reducing	O
the	O
incidence	O
and	O
severity	O
of	O
pain	O
due	O
to	O
propofol	O
injection	O
.	O


Shock	O
success	O
was	O
defined	O
as	O
return	B-OUT
of	I-OUT
sinus	I-OUT
rhythm	I-OUT
for	O
>	O
/=30	O
seconds	O
.	O


CONCLUSION	O
The	O
low-tilt	B-I
biphasic	I-I
waveform	I-I
was	O
more	O
successful	O
for	O
the	O
internal	O
cardioversion	O
of	O
both	O
persistent	O
and	O
induced	O
AF	B-P
in	I-P
patients	I-P
(	O
in	O
terms	O
of	O
leading	O
edge	O
voltage	O
)	O
.	O


AIM	O
In	O
our	O
randomized	O
prospective	O
study	O
,	O
we	O
aimed	O
to	O
evaluate	O
the	O
efficiency	O
of	O
plasmakinetic	B-I
resection	I-I
of	I-I
prostate	I-I
(	I-I
PKRP	I-I
)	I-I
by	O
comparing	O
the	O
preoperative	O
and	O
postoperative	O
results	O
of	O
the	O
transurethral	B-I
resection	I-I
of	I-I
prostate	I-I
(	O
TURP	O
)	O
and	O
PKRP	O
techniques	O
which	O
we	O
administered	O
in	O
patients	B-P
with	I-P
benign	I-P
prostate	I-P
hyperplasia	I-P
(	I-P
BPH	I-P
)	I-P
in	I-P
our	I-P
clinic	I-P
.	I-P


International	B-OUT
prostate	I-OUT
symptom	I-OUT
scores	I-OUT
(	I-OUT
I-PSS	I-OUT
)	I-OUT
,	I-OUT
uroflowmetry	I-OUT
,	I-OUT
measurement	I-OUT
of	I-OUT
residual	I-OUT
urine	I-OUT
amount	I-OUT
and	I-OUT
ultrasonography	I-OUT
were	O
performed	O
for	O
each	O
patient	O
both	O
preoperatively	O
and	O
postoperatively	O
(	O
first	O
month	O
and	O
first	O
year	O
)	O
.	O


Operation	B-OUT
times	I-OUT
,	I-OUT
urethral	I-OUT
catheterization	I-OUT
times	I-OUT
,	I-OUT
preoperative	I-OUT
and	I-OUT
postoperative	I-OUT
Hb	I-OUT
,	I-OUT
Htc	I-OUT
and	I-OUT
serum	I-OUT
Na	I-OUT
values	I-OUT
of	O
the	O
patients	O
were	O
compared	O
and	O
the	O
complications	O
of	O
the	O
groups	O
were	O
also	O
compared	O
.	O


The	O
decrease	O
in	O
serum	B-OUT
Na	I-OUT
level	I-OUT
was	O
found	O
to	O
be	O
significantly	O
higher	O
in	O
the	O
TURP	O
group	O
(	O
P	O
<	O
0.05	O
)	O
.	O


The	O
operation	B-OUT
times	I-OUT
were	O
not	O
significantly	O
different	O
between	O
the	O
groups	O
.	O


While	O
the	O
postoperative	B-OUT
catheterization	I-OUT
time	I-OUT
was	O
75.7	O
h	O
in	O
TURP	O
group	O
,	O
it	O
was	O
found	O
to	O
be	O
42	O
h	O
in	O
PKRP	O
group	O
and	O
it	O
was	O
clear	O
that	O
catheterization	B-OUT
time	I-OUT
was	O
significantly	O
shorter	O
(	O
P	O
<	O
0001	O
)	O
.	O


METHODS	O
The	O
relationship	O
between	O
ACE	O
genotype	O
and	O
the	O
response	O
to	O
11weeks	B-I
of	I-I
resistance	I-I
exercise	I-I
training	I-I
was	O
determined	O
in	O
37	B-P
CHF	I-P
patients	I-P
(	I-P
New	I-P
York	I-P
Heart	I-P
Association	I-P
Functional	I-P
Class=2.3±0.5	I-P
;	I-P
left	I-P
ventricular	I-P
ejection	I-P
fraction	I-P
28±7	I-P
%	I-P
;	I-P
age	I-P
64±12years	I-P
;	I-P
32:5	I-P
male	I-P
:	I-P
female	I-P
)	I-P
who	I-P
were	I-P
randomised	I-P
to	O
either	B-I
resistance	I-I
exercise	I-I
(	O
n=19	O
)	O
or	B-I
inactive	I-I
control	I-I
group	I-I
(	O
n=18	O
)	O
.	O


RESULTS	O
At	O
baseline	O
,	O
patients	O
who	O
were	O
homozygous	O
for	O
the	O
I	O
allele	O
had	O
higher	B-OUT
V˙O	I-OUT
(	I-OUT
2peak	I-OUT
)	I-OUT
(	I-OUT
p=0.02	I-OUT
)	I-OUT
and	I-OUT
peak	I-OUT
power	I-OUT
(	O
p=0.003	O
)	O
compared	O
to	O
patients	O
who	O
were	O
homozygous	O
for	O
the	O
D	O
allele	O
.	O


No	O
significant	O
genotype-dependent	O
changes	O
were	O
observed	B-OUT
in	I-OUT
V˙O	I-OUT
(	I-OUT
2peak	I-OUT
)	I-OUT
,	I-OUT
muscle	I-OUT
strength	I-OUT
,	I-OUT
muscle	I-OUT
endurance	I-OUT
or	I-OUT
lactate	I-OUT
threshold	I-OUT
.	O


The	O
acute	O
effects	O
of	O
fluid	O
intake	O
on	O
urine	O
specific	O
gravity	O
and	O
fluid	O
retention	O
in	O
a	B-P
mildly	I-P
dehydrated	I-P
state	I-P
.	I-P


Many	O
athletes	B-P
arrive	O
at	O
training	O
sessions	O
and	O
competitions	O
in	O
a	O
mildly	B-P
hypohydrated	I-P
(	I-P
HYPO	I-P
)	I-P
state	I-P
and	O
are	O
instructed	O
to	O
drink	O
fluids	O
before	O
exercise	O
to	O
reach	O
a	O
euhydrated	O
(	O
HYD	O
)	O
state	O
.	O


Following	O
baseline	O
(	O
6	O
weeks	O
)	O
,	O
patients	O
entered	O
a	O
19-week	O
double-blind	O
phase	B-I
:	I-I
6-week	I-I
titration	I-I
(	I-I
2	I-I
mg/week	I-I
increments	I-I
to	I-I
target	I-I
dose	I-I
)	I-I
followed	I-I
by	I-I
a	I-I
13-week	I-I
maintenance	I-I
period	I-I
.	O


Using	O
this	O
intent-to-treat	O
population	O
over	O
the	O
double-blind	O
phase	O
,	O
the	B-OUT
median	I-OUT
percent	I-OUT
change	I-OUT
in	I-OUT
seizure	I-OUT
frequency	I-OUT
was	O
-21.0	O
%	O
,	O
-26.3	O
%	O
,	O
and	O
-34.5	O
%	O
for	B-I
placebo	I-I
and	I-I
perampanel	I-I
8	O
and	O
12	O
mg	O
,	O
respectively	O
(	O
p	O
=	O
0.0261	O
and	O
p	O
=	O
0.0158	O
for	O
8	O
and	O
12	O
mg	O
vs	O
placebo	O
,	O
respectively	O
)	O
.	O


Fifty	O
percent	O
responder	O
rates	O
during	O
the	O
maintenance	O
period	O
were	O
26.4	O
%	O
,	O
37.6	O
%	O
,	O
and	O
36.1	O
%	O
,	O
respectively	O
,	O
for	B-I
placebo	I-I
,	I-I
perampanel	I-I
8	O
mg	O
,	O
and	B-I
perampanel	I-I
12	O
mg	O
;	O
these	O
differences	O
were	O
not	O
statistically	O
significant	O
for	O
8	O
mg	O
(	O
p	O
=	O
0.0760	O
)	O
or	O
12	O
mg	O
(	O
p	O
=	O
0.0914	B-P
)	I-P
.	I-P


Sixty-eight	B-P
(	I-P
17.5	I-P
%	I-P
)	I-P
patients	I-P
discontinued	I-P
,	I-P
including	I-P
40	I-P
(	I-P
10.3	I-P
%	I-P
)	I-P
for	I-P
adverse	I-P
events	I-P
.	O


CONCLUSIONS	O
This	O
trial	O
demonstrated	O
that	O
once-daily	O
,	O
adjunctive	B-I
perampanel	I-I
at	O
doses	O
of	O
8	O
or	O
12	O
mg	O
improved	B-OUT
seizure	I-OUT
control	I-OUT
in	I-P
patients	I-P
with	I-P
uncontrolled	I-P
partial-onset	I-P
seizures	I-P
.	O


CLASSIFICATION	O
OF	O
EVIDENCE	O
This	O
study	O
provides	O
Class	O
I	O
evidence	O
that	O
once-daily	O
8	O
and	O
12	O
mg	O
doses	O
of	O
adjunctive	B-I
perampanel	I-I
are	O
effective	O
in	O
patients	O
with	O
uncontrolled	O
partial-onset	O
seizures	O
.	O
